<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="protocol"><front><journal-meta><journal-id journal-id-type="nlm-ta">BMJ Open</journal-id><journal-id journal-id-type="iso-abbrev">BMJ Open</journal-id><journal-id journal-id-type="hwp">bmjopen</journal-id><journal-id journal-id-type="publisher-id">bmjopen</journal-id><journal-title-group><journal-title>BMJ Open</journal-title></journal-title-group><issn pub-type="epub">2044-6055</issn><publisher><publisher-name>BMJ Publishing Group</publisher-name><publisher-loc>BMA House, Tavistock Square, London, WC1H 9JR</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">28790042</article-id><article-id pub-id-type="pmc">5724199</article-id><article-id pub-id-type="publisher-id">bmjopen-2017-017003</article-id><article-id pub-id-type="doi">10.1136/bmjopen-2017-017003</article-id><article-categories><subj-group subj-group-type="heading"><subject>Intensive Care</subject><subj-group><subject>Protocol</subject></subj-group></subj-group><subj-group subj-group-type="hwp-journal-coll"><subject>1506</subject><subject>1707</subject><subject>1706</subject></subj-group></article-categories><title-group><article-title>Multicentre randomised controlled trial to investigate the usefulness of continuous pneumatic regulation of tracheal cuff pressure for reducing ventilator-associated pneumonia in mechanically ventilated severe trauma patients: the AGATE study protocol</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Marjanovic</surname><given-names>Nicolas</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Frasca</surname><given-names>Denis</given-names></name><xref ref-type="aff" rid="aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Asehnoune</surname><given-names>Karim</given-names></name><xref ref-type="aff" rid="aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Paugam</surname><given-names>Catherine</given-names></name><xref ref-type="aff" rid="aff4">4</xref></contrib><contrib contrib-type="author"><name><surname>Lasocki</surname><given-names>Sigismond</given-names></name><xref ref-type="aff" rid="aff5">5</xref></contrib><contrib contrib-type="author"><name><surname>Ichai</surname><given-names>Carole</given-names></name><xref ref-type="aff" rid="aff6">6</xref></contrib><contrib contrib-type="author"><name><surname>Lefrant</surname><given-names>Jean-Yves</given-names></name><xref ref-type="aff" rid="aff7">7</xref></contrib><contrib contrib-type="author"><name><surname>Leone</surname><given-names>Marc</given-names></name><xref ref-type="aff" rid="aff8">8</xref></contrib><contrib contrib-type="author"><name><surname>Dahyot-Fizelier</surname><given-names>Claire</given-names></name><xref ref-type="aff" rid="aff9">9</xref></contrib><contrib contrib-type="author"><name><surname>Pottecher</surname><given-names>Julien</given-names></name><xref ref-type="aff" rid="aff10">10</xref></contrib><contrib contrib-type="author"><name><surname>Falcon</surname><given-names>Dominique</given-names></name><xref ref-type="aff" rid="aff11">11</xref></contrib><contrib contrib-type="author"><name><surname>Veber</surname><given-names>Benoit</given-names></name><xref ref-type="aff" rid="aff12">12</xref></contrib><contrib contrib-type="author"><name><surname>Constantin</surname><given-names>Jean-Michel</given-names></name><xref ref-type="aff" rid="aff13">13</xref></contrib><contrib contrib-type="author"><name><surname>Seguin</surname><given-names>Sabrina</given-names></name><xref ref-type="aff" rid="aff14">14</xref></contrib><contrib contrib-type="author"><name><surname>Guénézan</surname><given-names>Jérémy</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Mimoz</surname><given-names>Olivier</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff15">15</xref></contrib><on-behalf-of>For the AGATE study group</on-behalf-of></contrib-group><contrib-group content-type="collaborators"><contrib contrib-type="collab"><collab>AGATE study group</collab></contrib><contrib contrib-type="collab"><name><surname>Ambert</surname><given-names>Audrey</given-names></name></contrib><contrib contrib-type="collab"><name><surname>Audibert</surname><given-names>Gérard</given-names></name></contrib><contrib contrib-type="collab"><name><surname>Bergis</surname><given-names>Alexandre</given-names></name></contrib><contrib contrib-type="collab"><name><surname>Bouhemad</surname><given-names>Belaid</given-names></name></contrib><contrib contrib-type="collab"><name><surname>Caumon</surname><given-names>Elodie</given-names></name></contrib><contrib contrib-type="collab"><name><surname>Cinotti</surname><given-names>Raphael</given-names></name></contrib><contrib contrib-type="collab"><name><surname>Diop</surname><given-names>Aminata</given-names></name></contrib><contrib contrib-type="collab"><name><surname>Drevet</surname><given-names>Claire-Marie</given-names></name></contrib><contrib contrib-type="collab"><name><surname>Duranteau</surname><given-names>Jacques</given-names></name></contrib><contrib contrib-type="collab"><name><surname>Dumont</surname><given-names>Nathalie</given-names></name></contrib><contrib contrib-type="collab"><name><surname>Fourcrier</surname><given-names>Arnaud</given-names></name></contrib><contrib contrib-type="collab"><name><surname>Gaillard</surname><given-names>Thomas</given-names></name></contrib><contrib contrib-type="collab"><name><surname>Guérin</surname><given-names>Anne-Laure</given-names></name></contrib><contrib contrib-type="collab"><name><surname>Guyon</surname><given-names>Marion</given-names></name></contrib><contrib contrib-type="collab"><name><surname>Hecketsweiler</surname><given-names>Stéphane</given-names></name></contrib><contrib contrib-type="collab"><name><surname>Imzi</surname><given-names>Nadia</given-names></name></contrib><contrib contrib-type="collab"><name><surname>Lamacz</surname><given-names>Anna</given-names></name></contrib><contrib contrib-type="collab"><name><surname>Laplace</surname><given-names>Christian</given-names></name></contrib><contrib contrib-type="collab"><name><surname>Leduc</surname><given-names>Sébastien</given-names></name></contrib><contrib contrib-type="collab"><name><surname>Loiez</surname><given-names>Anthéa</given-names></name></contrib><contrib contrib-type="collab"><name><surname>Lloret</surname><given-names>Sophie</given-names></name></contrib><contrib contrib-type="collab"><name><surname>Manhes</surname><given-names>Pauline</given-names></name></contrib><contrib contrib-type="collab"><name><surname>Payen</surname><given-names>Jean-Pierre</given-names></name></contrib><contrib contrib-type="collab"><name><surname>Pilifloury</surname><given-names>Sébastien</given-names></name></contrib><contrib contrib-type="collab"><name><surname>Roquilly</surname><given-names>Antoine</given-names></name></contrib><contrib contrib-type="collab"><name><surname>Vettoretti</surname><given-names>Lucie</given-names></name></contrib></contrib-group><aff id="aff1">
<label>1</label>
<institution content-type="department">Department of Emergency and Prehospital Care</institution>, <institution>Centre Hospitalier Universitaire de Poitiers</institution>, <addr-line content-type="city">Poitiers</addr-line>, <country>France</country>
</aff><aff id="aff2">
<label>2</label>
<institution>INSERM UMR1246—Methods in Patient-Centered Outcomes and Health Research</institution>, <addr-line content-type="city">Poitiers</addr-line>, <country>France</country>
</aff><aff id="aff3">
<label>3</label>
<institution>Centre Hospitalier Universitaire de Nantes, Anaesthesia and Intensive Care Unit</institution>, <addr-line content-type="city">Nantes</addr-line>, <country>France</country>
</aff><aff id="aff4">
<label>4</label>
<institution>Assistance Publique des Hôpitaux de Paris, Intensive Care Unit, Hôpital Beaujon</institution>, <addr-line content-type="city">Clichy</addr-line>, <country>France</country>
</aff><aff id="aff5">
<label>5</label>
<institution>Centre Hospitalier Universitaire d’Angers, Intensive Care Unit</institution>, <addr-line content-type="city">Angers</addr-line>, <country>France</country>
</aff><aff id="aff6">
<label>6</label>
<institution>Centre Hospitalier Universitaire de Nice, Intensive Care Unit</institution>, <addr-line content-type="city">Nice</addr-line>, <country>France</country>
</aff><aff id="aff7">
<label>7</label>
<institution content-type="department">Division Anaesthesia Critical Care, Emergency and Pain Medicine</institution>, <institution>Centre Hospitalier Universitaire de Nimes</institution>, <addr-line content-type="city">Nimes</addr-line>, <country>France</country>
</aff><aff id="aff8">
<label>8</label>
<institution>Assistance Publique Hopitaux de Marseille, Intensive Care Unit, Hôpital Nord</institution>, <addr-line content-type="city">Marseille</addr-line>, <country>France</country>
</aff><aff id="aff9">
<label>9</label>
<institution>Centre Hospitalier Universitaire de Poitiers, Neuro-Intensive Care Unit</institution>, <addr-line content-type="city">Poitiers</addr-line>, <country>France</country>
</aff><aff id="aff10">
<label>10</label>
<institution>Hopitaux Universitaires de Strasbourg, Intensive Care Unit</institution>, <addr-line content-type="city">Strasbourg</addr-line>, <country>France</country>
</aff><aff id="aff11">
<label>11</label>
<institution>Centre Hospitalier Universitaire de Grenoble, Intensive Care Unit</institution>, <addr-line content-type="city">Grenoble</addr-line>, <country>France</country>
</aff><aff id="aff12">
<label>12</label>
<institution>Centre Hospitalier Universitaire de Rouen, Intensive Care Unit</institution>, <addr-line content-type="city">Rouen</addr-line>, <country>France</country>
</aff><aff id="aff13">
<label>13</label>
<institution>Centre Hospitalier Universitaire de Clermont-Ferrand, Intensive Care Unit</institution>, <addr-line content-type="city">Clermont-Ferrand</addr-line>, <country>France</country>
</aff><aff id="aff14">
<label>14</label>
<institution content-type="department">Department of Emergency and Prehospital Care</institution>, <institution>Centre Hospitalier Universitaire de Poitiers, Intensive Care Unit</institution>, <addr-line content-type="city">Poitiers</addr-line>, <country>France</country>
</aff><aff id="aff15">
<label>15</label>
<institution>INSERM U1070, Université de Poitiers</institution>, <addr-line content-type="city">Poitiers</addr-line>, <country>France</country>
</aff><author-notes><corresp><label>Correspondence to</label> Professor Olivier Mimoz; <email>olivier.mimoz@wanadoo.fr</email></corresp></author-notes><pub-date pub-type="collection"><year>2017</year></pub-date><pub-date pub-type="epub"><day>7</day><month>8</month><year>2017</year></pub-date><volume>7</volume><issue>8</issue><elocation-id>e017003</elocation-id><history><date date-type="received"><day>27</day><month>3</month><year>2017</year></date><date date-type="rev-recd"><day>17</day><month>5</month><year>2017</year></date><date date-type="accepted"><day>14</day><month>6</month><year>2017</year></date></history><permissions><copyright-statement>© Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2017. All rights reserved. No commercial use is permitted unless otherwise expressly granted.</copyright-statement><copyright-year>2017</copyright-year><license license-type="open-access"><license-p>This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc/4.0/">http://creativecommons.org/licenses/by-nc/4.0/</ext-link></license-p></license></permissions><self-uri xlink:title="pdf" xlink:href="bmjopen-2017-017003.pdf"></self-uri><self-uri content-type="reviewers-comments-pdf" xlink:href="bmjopen-2017-017003.reviewer_comments.pdf"></self-uri><self-uri content-type="draft-revisions-pdf" xlink:href="bmjopen-2017-017003.draft_revisions.pdf"></self-uri><abstract><sec><title><offsets xml_i="12527" xml_f="12539" txt_i="11" txt_f="23">Introduction</offsets></title><p><offsets xml_i="12550" xml_f="13289" txt_i="24" txt_f="763">Severe trauma represents the leading cause of mortality worldwide. While 80% of deaths occur within the first 24 hours after trauma, 20% occur later and are mainly due to healthcare-associated infections, including ventilator-associated pneumonia (VAP). Preventing underinflation of the tracheal cuff is recommended to reduce microaspiration, which plays a major role in the pathogenesis of VAP. Automatic devices facilitate the regulation of tracheal cuff pressure, and their implementation has the potential to reduce VAP. The objective of this work is to determine whether continuous regulation of tracheal cuff pressure using a pneumatic device reduces the incidence of VAP compared with intermittent control in severe trauma patients.</offsets></p></sec><sec><title><offsets xml_i="13311" xml_f="13331" txt_i="765" txt_f="785">Methods and analysis</offsets></title><p><offsets xml_i="13342" xml_f="14186" txt_i="786" txt_f="1627">This multicentre randomised controlled and open-label trial will include patients suffering from severe trauma who are admitted within the first 24 hours, who require invasive mechanical ventilation to longer than 48 hours. Their tracheal cuff pressure will be monitored either once every 8 hours (control group) or continuously using a pneumatic device (intervention group). The primary end point is the proportion of patients that develop VAP in the intensive care unit (ICU) at day 28. The secondary end points include the proportion of patients that develop VAP in the ICU, early (≤7 days) or late (&gt;7 days) VAP, time until the first VAP diagnosis, the number of ventilator-free days and antibiotic-free days, the length of stay in the ICU, the proportion of patients with ventilator-associated events and that die during their ICU stay.</offsets></p></sec><sec><title><offsets xml_i="14208" xml_f="14232" txt_i="1629" txt_f="1653">Ethics and dissemination</offsets></title><p><offsets xml_i="14243" xml_f="14594" txt_i="1654" txt_f="2005">This protocol has been approved by the ethics committee of Poitiers University Hospital, and will be carried out according to the principles of the Declaration of Helsinki and the Good Clinical Practice guidelines. The results of this study will be disseminated through presentation at scientific conferences and publication in peer-reviewed journals.</offsets></p></sec><sec><title><offsets xml_i="14616" xml_f="14634" txt_i="2007" txt_f="2025">Trial registration</offsets></title><p><offsets xml_i="14645" xml_f="14672" txt_i="2026" txt_f="2053">Clinical Trials NCT02534974</offsets></p></sec></abstract><kwd-group><kwd>pneumonia</kwd><kwd>wounds and injuries</kwd><kwd>pneumonia, ventilator-asssociated</kwd><kwd>lung diseases</kwd><kwd>respiratory tract diseases</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>special-feature</meta-name><meta-value>unlocked</meta-value></custom-meta></custom-meta-group></article-meta></front><body><boxed-text id="BX1" position="float" orientation="portrait"><caption><title><offsets xml_i="15114" xml_f="15153" txt_i="2062" txt_f="2101">Strengths and limitations of this study</offsets></title></caption><list list-type="bullet"><list-item><p><offsets xml_i="15210" xml_f="15469" txt_i="2102" txt_f="2361">This study will be conducted as a multicentre randomised controlled and open-label trial adequately powered to determine whether continuous regulation of tracheal cuff pressure using a pneumatic device reduces the incidence of ventilator-associated pneumonia.</offsets></p></list-item><list-item><p><offsets xml_i="15499" xml_f="15656" txt_i="2362" txt_f="2519">This will be the first large study on that topic with the potential of changing international recommendations on ventilation-associated pneumonia prevention.</offsets></p></list-item><list-item><p><offsets xml_i="15686" xml_f="15851" txt_i="2520" txt_f="2685">Study’s benefits include reduced duration of mechanical ventilation and stay in the intensive care unit, improved patient prognosis and reduction in antibiotics use.</offsets></p></list-item><list-item><p><offsets xml_i="15881" xml_f="16007" txt_i="2686" txt_f="2812">Limitations due to the lack of masking related to the nature of the intervention are limited by a masked end point assessment.</offsets></p></list-item></list></boxed-text><sec sec-type="intro" id="s1"><title><offsets xml_i="16080" xml_f="16092" txt_i="2813" txt_f="2825">Introduction</offsets></title><sec id="s1a"><title><offsets xml_i="16121" xml_f="16145" txt_i="2826" txt_f="2850">Background and rationale</offsets></title><p><offsets xml_i="16156" xml_f="16438" txt_i="2851" txt_f="3133">Severe trauma represents the leading cause of mortality worldwide, and is the third highest cause of death in France behind cardiovascular disease and cancer. About 46 deaths following trauma occur per 1 00 000 inhabitants per year in France, representing close to 8% of all deaths.</offsets><xref rid="R1" ref-type="bibr"><offsets xml_i="16469" xml_f="16472" txt_i="3133" txt_f="3136">1 2</offsets></xref><offsets xml_i="16479" xml_f="16669" txt_i="3136" txt_f="3326"> While 80% of deaths occur within the first 24 hours of trauma, directly related to the trauma itself, 20% of deaths occur later and are mainly due to healthcare-associated infections (HAI).</offsets><xref rid="R3" ref-type="bibr"><offsets xml_i="16700" xml_f="16703" txt_i="3326" txt_f="3329">3–6</offsets></xref><offsets xml_i="16710" xml_f="17070" txt_i="3329" txt_f="3689"> More than 50% of patients that present with severe trauma will develop at least one HAI during their stay. Neurological disorders, recourse to mechanical ventilation and early post-traumatic immune suppression may explain the elevated incidence of HAI, particularly ventilator-associated pneumonia (VAP), which mainly occur in the first week following trauma.</offsets><xref rid="R7" ref-type="bibr"><offsets xml_i="17101" xml_f="17104" txt_i="3689" txt_f="3692">7–9</offsets></xref></p><p><offsets xml_i="17118" xml_f="17299" txt_i="3693" txt_f="3874">VAP represents the predominant HAI in severe trauma patients with a mean incidence of 35%, which may even exceed 60% in some series, followed by catheter infections and bacteraemia.</offsets><xref rid="R3" ref-type="bibr"><offsets xml_i="17330" xml_f="17333" txt_i="3874" txt_f="3877">3–6</offsets></xref><offsets xml_i="17340" xml_f="17539" txt_i="3877" txt_f="4076"> HAI account for heightened morbidity and mortality, longer stays in the intensive care unit (ICU) and increased treatment costs. In France, the additional cost is estimated at €800 million per year.</offsets><xref rid="R1" ref-type="bibr"><offsets xml_i="17570" xml_f="17571" txt_i="4076" txt_f="4077">1</offsets></xref><offsets xml_i="17578" xml_f="17723" txt_i="4077" txt_f="4222"> These infections also require high use of antibiotics, and VAP alone makes up more than half of the antibiotic treatments prescribed in the ICU.</offsets><xref rid="R7" ref-type="bibr"><offsets xml_i="17754" xml_f="17755" txt_i="4222" txt_f="4223">7</offsets></xref><offsets xml_i="17762" xml_f="17878" txt_i="4223" txt_f="4339"> Given the selection pressure they induce, these antibiotic therapies favour the appearance of bacterial resistance.</offsets></p><sec id="s1a1"><title><offsets xml_i="17904" xml_f="17923" txt_i="4340" txt_f="4359">VAP pathophysiology</offsets></title><p><offsets xml_i="17934" xml_f="18295" txt_i="4360" txt_f="4721">The presence of a foreign material (tracheal tube or stomach tube) facilitates colonisation of the upper airways and digestive tract by endogenous and exogenous microorganisms. Tracheal contamination originates through bacterial aspiration, resulting from the passage of secretions from around the cuff of the tracheal tube accumulating above the tracheal cuff.</offsets><xref rid="R10" ref-type="bibr"><offsets xml_i="18327" xml_f="18329" txt_i="4721" txt_f="4723">10</offsets></xref><offsets xml_i="18336" xml_f="18524" txt_i="4723" txt_f="4911"> More rarely, VAP can arise from contaminated stagnant water in the ventilator circuit, use of colonised aerosols or a contaminated contiguous site (almost exclusively the pleural cavity).</offsets><xref rid="R11" ref-type="bibr"><offsets xml_i="18556" xml_f="18558" txt_i="4911" txt_f="4913">11</offsets></xref></p></sec><sec id="s1a2"><title><offsets xml_i="18597" xml_f="18624" txt_i="4915" txt_f="4942">Prevention measures for VAP</offsets></title><p><offsets xml_i="18635" xml_f="18861" txt_i="4943" txt_f="5169">Enhanced knowledge of the pathophysiology of VAP has led to the development of effective preventive strategies. The VAP prevention measures recommended by the 2008 French consensus conference on nosocomial infection prevention</offsets><xref rid="R12" ref-type="bibr"><offsets xml_i="18893" xml_f="18895" txt_i="5169" txt_f="5171">12</offsets></xref><offsets xml_i="18902" xml_f="19002" txt_i="5171" txt_f="5271"> state that the orotracheal route should be used for tracheal intubation instead of the nasal route,</offsets><xref rid="R7" ref-type="bibr"><offsets xml_i="19033" xml_f="19040" txt_i="5271" txt_f="5278">7 11 13</offsets></xref><offsets xml_i="19047" xml_f="19122" txt_i="5278" txt_f="5353"> and the tracheal cuff pressure should be maintained between 25 and 30 cm H</offsets><sub><offsets xml_i="19127" xml_f="19128" txt_i="5353" txt_f="5354">2</offsets></sub><offsets xml_i="19134" xml_f="19136" txt_i="5354" txt_f="5356">O.</offsets><xref rid="R14" ref-type="bibr"><offsets xml_i="19168" xml_f="19173" txt_i="5356" txt_f="5361">14 15</offsets></xref><offsets xml_i="19180" xml_f="19320" txt_i="5361" txt_f="5501"> They also recommend using a sedation-analgesia algorithm that facilitates early weaning off ventilation, avoidance of unplanned extubation,</offsets><xref rid="R16" ref-type="bibr"><offsets xml_i="19352" xml_f="19354" txt_i="5501" txt_f="5503">16</offsets></xref><offsets xml_i="19361" xml_f="19451" txt_i="5503" txt_f="5593"> prioritising the use of non-invasive ventilation by following the recognised indications,</offsets><xref rid="R16" ref-type="bibr"><offsets xml_i="19483" xml_f="19488" txt_i="5593" txt_f="5598">16 17</offsets></xref><offsets xml_i="19495" xml_f="19565" txt_i="5598" txt_f="5668"> placing the patient in a semi-recumbent position between 30° and 45°,</offsets><xref rid="R18" ref-type="bibr"><offsets xml_i="19597" xml_f="19602" txt_i="5668" txt_f="5673">18 19</offsets></xref><offsets xml_i="19609" xml_f="19698" txt_i="5673" txt_f="5762"> regularly decontaminating the nasal and oropharyngeal cavity through suitable mouth care</offsets><xref rid="R20" ref-type="bibr"><offsets xml_i="19730" xml_f="19735" txt_i="5762" txt_f="5767">20 21</offsets></xref><offsets xml_i="19742" xml_f="19795" txt_i="5767" txt_f="5820"> and starting enteral nutrition as early as possible.</offsets><xref rid="R22" ref-type="bibr"><offsets xml_i="19827" xml_f="19829" txt_i="5820" txt_f="5822">22</offsets></xref><offsets xml_i="19836" xml_f="20122" txt_i="5822" txt_f="6108"> When combined with systemic antibiotic therapy, selective digestive decontamination may be recommended, but its implementation requires specification of its modalities (choice, dosing, duration of selective digestive decontamination and antibiotic therapy) and the targeted population.</offsets></p><p><offsets xml_i="20129" xml_f="20394" txt_i="6109" txt_f="6374">Maintaining a sufficient level of pressure in the tracheal tube cuff is of critical importance. When the pressure is too low, the patient risks inhaling the accumulated subglottic secretions from the oropharynx, which is known to play a major role in VAP incidence.</offsets><xref rid="R14" ref-type="bibr"><offsets xml_i="20426" xml_f="20431" txt_i="6374" txt_f="6379">14 15</offsets></xref><offsets xml_i="20438" xml_f="20970" txt_i="6379" txt_f="6911"> Alternatively, if the pressure is too high there is a risk of ischaemia of the tracheal mucosa and, at removal, of tracheal oedema and later tracheal stenosis. Therefore, regular monitoring of tracheal cuff pressure is recommended, but the optimal monitoring frequency has yet to be clearly determined. Underinflation and/or overinflation of the tracheal cuff often occurs in ventilated patients under intermittent manual control of tracheal cuff pressure using a manometer, which is a well-known source of morbidity and mortality.</offsets><xref rid="R23" ref-type="bibr"><offsets xml_i="21002" xml_f="21004" txt_i="6911" txt_f="6913">23</offsets></xref><offsets xml_i="21011" xml_f="21134" txt_i="6913" txt_f="7036"> Recently published data favour use of automatic devices that are able to continuously regulate the tracheal cuff pressure.</offsets><xref rid="R24" ref-type="bibr"><offsets xml_i="21166" xml_f="21171" txt_i="7036" txt_f="7041">24–31</offsets></xref><offsets xml_i="21178" xml_f="21372" txt_i="7041" txt_f="7235"> Even though several learned societies do not recommend their implementation for the purpose of VAP prevention in ventilated patients, recent findings in the literature tend to favour their use.</offsets><xref rid="R24" ref-type="bibr"><offsets xml_i="21404" xml_f="21418" txt_i="7235" txt_f="7249">24 25 27 29 32</offsets></xref><offsets xml_i="21425" xml_f="21800" txt_i="7249" txt_f="7624"> However, these studies have several limitations, as all were monocentre studies that included a relatively small number of participants, which rarely included severe trauma patients even though they are at greatest risk for VAP, and these studies did not systematically apply other recommended VAP preventive measures, with a contestable choice for the main study end point.</offsets></p><p><offsets xml_i="21807" xml_f="21945" txt_i="7625" txt_f="7763">Two methods of continuous regulation of tracheal cuff pressure are available: pneumatic and electronic. Published studies favour the first</offsets><xref rid="R33" ref-type="bibr"><offsets xml_i="21977" xml_f="21979" txt_i="7763" txt_f="7765">33</offsets></xref><offsets xml_i="21986" xml_f="22248" txt_i="7765" txt_f="8027"> due to better reactivity with fewer periods of insufficient or excessive tracheal cuff pressure, and consequently, reduced risk of microbe inhalation and tracheal injuries, in addition to the low acquisition cost, ease of use and no electricity supply required.</offsets></p></sec></sec><sec id="s1b"><title><offsets xml_i="22285" xml_f="22295" txt_i="8030" txt_f="8040">Objectives</offsets></title><p><offsets xml_i="22306" xml_f="23047" txt_i="8041" txt_f="8782">The objective of this study is to determine whether continuous regulation of tracheal cuff pressure using a mechanical pneumatic regulation device (Nosten, Leved, Paris) is superior to intermittent control of tracheal cuff pressure for reducing the incidence of VAP in severe trauma patients, who will receive all other recommended methods of VAP prevention. At an individual level, the benefits are expected to include a shorter duration of mechanical ventilation and stay in the ICU, as well as improved patient outcomes. At a collective level, in addition to reduced cost of hospital stay, the number of days on antibiotics should also decline, along with the selective pressure perpetuating the emergence of multidrug-resistant bacteria.</offsets></p></sec><sec id="s1c"><title><offsets xml_i="23078" xml_f="23090" txt_i="8784" txt_f="8796">Study design</offsets></title><p><offsets xml_i="23101" xml_f="23536" txt_i="8797" txt_f="9232">The AGATE trial is a multicentre randomised controlled and open-label clinical trial with two parallel groups, with the primary end point being the proportion of patients that develop VAP in the ICU at day 28. Randomisation will be carried out through a secure web-based randomisation system, stratified by the centre and severity of patient unconsciousness at the time of inclusion (Glasgow Coma Scale lower and higher or equal to 8).</offsets></p></sec></sec><sec id="s2"><title><offsets xml_i="23572" xml_f="23592" txt_i="9235" txt_f="9255">Methods and analysis</offsets></title><sec id="s2a"><title><offsets xml_i="23621" xml_f="23633" txt_i="9256" txt_f="9268">Participants</offsets></title><p><offsets xml_i="23644" xml_f="23789" txt_i="9269" txt_f="9414">Patients will be considered candidates for inclusion in the study if they meet all of the inclusion criteria and none of the exclusion criteria (</offsets><xref ref-type="boxed-text" rid="BX2"><offsets xml_i="23827" xml_f="23832" txt_i="9414" txt_f="9419">box 1</offsets></xref><offsets xml_i="23839" xml_f="24362" txt_i="9419" txt_f="9942">). Patients suffering from severe trauma admitted within the first 24 hours, who require invasive mechanical ventilation expected to last longer than 48 hours, should be included in the study. For all cases, patient inclusion will take place as soon as possible after ICU admission, during the 24 hours following trauma and/or over the 15 hours following oral intubation of the trachea. Pregnant or lactating women can be included in the study because the material used does not present any specific risk of teratogenicity.</offsets><boxed-text id="BX2" position="float" orientation="portrait"><label><offsets xml_i="24430" xml_f="24435" txt_i="9942" txt_f="9947">Box 1</offsets></label><caption><title><offsets xml_i="24459" xml_f="24491" txt_i="9947" txt_f="9979">Inclusion and exclusion criteria</offsets></title></caption><p><offsets xml_i="24512" xml_f="24513" txt_i="9980" txt_f="9981">
</offsets><bold><offsets xml_i="24519" xml_f="24537" txt_i="9981" txt_f="9999">Inclusion criteria</offsets></bold></p><list list-type="order"><list-item><p><offsets xml_i="24586" xml_f="24617" txt_i="10000" txt_f="10031">Patients aged at least 18 years</offsets></p></list-item><list-item><p><offsets xml_i="24647" xml_f="24723" txt_i="10032" txt_f="10105">Suffering from a severe trauma as defined by an Injury Severity Score &gt;15</offsets></p></list-item><list-item><p><offsets xml_i="24753" xml_f="24818" txt_i="10106" txt_f="10168">With their tracheal intubated via the oral route for &lt;15 hours</offsets></p></list-item><list-item><p><offsets xml_i="24848" xml_f="24914" txt_i="10169" txt_f="10235">Requiring mechanical ventilation for an expected length ≥48 hours.</offsets></p></list-item><list-item><p><offsets xml_i="24944" xml_f="25044" txt_i="10236" txt_f="10336">Participating in a social security scheme or benefiting from such a scheme by means of a third party</offsets></p></list-item></list><p><offsets xml_i="25070" xml_f="25071" txt_i="10337" txt_f="10338">
</offsets><bold><offsets xml_i="25077" xml_f="25095" txt_i="10338" txt_f="10356">Exclusion criteria</offsets></bold></p><list list-type="order"><list-item><p><offsets xml_i="25144" xml_f="25201" txt_i="10357" txt_f="10414">Patient likely to die in the 48 hours following admission</offsets></p></list-item><list-item><p><offsets xml_i="25231" xml_f="25281" txt_i="10415" txt_f="10465">Having their trachea intubated via the nasal route</offsets></p></list-item><list-item><p><offsets xml_i="25311" xml_f="25387" txt_i="10466" txt_f="10542">Patient intubated through a tracheal tube with subglottic secretion drainage</offsets></p></list-item><list-item><p><offsets xml_i="25417" xml_f="25477" txt_i="10543" txt_f="10603">Having their trachea intubated 24 hours or more after trauma</offsets></p></list-item><list-item><p><offsets xml_i="25507" xml_f="25540" txt_i="10604" txt_f="10637">Being ventilated with tracheotomy</offsets></p></list-item><list-item><p><offsets xml_i="25570" xml_f="25609" txt_i="10638" txt_f="10677">Refusing to participate in the research</offsets></p></list-item><list-item><p><offsets xml_i="25639" xml_f="25686" txt_i="10678" txt_f="10725">Having contraindication to the head-up position</offsets></p></list-item><list-item><p><offsets xml_i="25716" xml_f="25845" txt_i="10726" txt_f="10855">Participating in another research protocol pertaining to an anti-infective treatment or to a measure decreasing risk of infection</offsets></p></list-item><list-item><p><offsets xml_i="25875" xml_f="26023" txt_i="10856" txt_f="11004">Benefiting from reinforced protection or persons deprived of freedom subsequent to a legal or administrative decision, majors under legal protection</offsets></p></list-item></list></boxed-text></p></sec><sec id="s2b"><title><offsets xml_i="26090" xml_f="26103" txt_i="11007" txt_f="11020">Interventions</offsets></title><p><offsets xml_i="26114" xml_f="26464" txt_i="11021" txt_f="11371">All of the patients included in the study will be randomised in one of the two treatment groups, which are based on the method used to monitor tracheal cuff pressure and benefit from daily monitoring throughout their hospital stay in the ICU. The following criteria will be applied to all patients and controlled throughout the duration of the study.</offsets><list list-type="bullet"><list-item><p><offsets xml_i="26503" xml_f="26763" txt_i="11371" txt_f="11631">Monitoring of tracheal cuff pressure of the tracheal tube either once every 8 hours in the control group or continuously in the intervention group through the use of a pneumatic device (Nosten), with the objective of maintaining pressure between 25 and 30 cm H</offsets><sub><offsets xml_i="26768" xml_f="26769" txt_i="11631" txt_f="11632">2</offsets></sub><offsets xml_i="26775" xml_f="26777" txt_i="11632" txt_f="11634">O.</offsets></p></list-item><list-item><p><offsets xml_i="26807" xml_f="26882" txt_i="11635" txt_f="11710">Implementation of identical sedation and weaning protocols for all centres.</offsets></p></list-item><list-item><p><offsets xml_i="26912" xml_f="26968" txt_i="11711" txt_f="11767">Implementation of a lung protective ventilation strategy</offsets><xref rid="R34" ref-type="bibr"><offsets xml_i="27000" xml_f="27002" txt_i="11767" txt_f="11769">34</offsets></xref><offsets xml_i="27009" xml_f="27118" txt_i="11769" txt_f="11875"> by maintaining a tidal volume of 6–8 mL/kg of ideal body weight, positive end-expiratory pressure &gt;3 cm H</offsets><sub><offsets xml_i="27123" xml_f="27124" txt_i="11875" txt_f="11876">2</offsets></sub><offsets xml_i="27130" xml_f="27212" txt_i="11876" txt_f="11958">O and respiratory rate set to achieve normocapnia or optional moderate hypocapnia.</offsets></p></list-item><list-item><p><offsets xml_i="27242" xml_f="27513" txt_i="11959" txt_f="12224">According to the protocol observed in the unit, extubation should be considered as soon as: (1) the patient’s Glasgow Coma Scale is &gt;10; (2) the patient is coughing spontaneously or secondary to bronchial aspiration and (3) the level of pressure support is &lt;10 cm H</offsets><sub><offsets xml_i="27518" xml_f="27519" txt_i="12224" txt_f="12225">2</offsets></sub><offsets xml_i="27525" xml_f="27574" txt_i="12225" txt_f="12274">O, or spontaneous ventilation on a T-piece with F</offsets><sub><offsets xml_i="27579" xml_f="27580" txt_i="12274" txt_f="12275">i</offsets></sub><offsets xml_i="27586" xml_f="27587" txt_i="12275" txt_f="12276">O</offsets><sub><offsets xml_i="27592" xml_f="27593" txt_i="12276" txt_f="12277">2</offsets></sub><offsets xml_i="27599" xml_f="27663" txt_i="12277" txt_f="12341"> lower than 40% is tolerated by the patient for at least 30 min.</offsets></p></list-item><list-item><p><offsets xml_i="27693" xml_f="27742" txt_i="12342" txt_f="12391">No systematic changes to the respirator circuits.</offsets></p></list-item><list-item><p><offsets xml_i="27772" xml_f="27858" txt_i="12392" txt_f="12478">Preferential use of heat and humidity exchange filters to be changed only when soiled.</offsets></p></list-item><list-item><p><offsets xml_i="27888" xml_f="27976" txt_i="12479" txt_f="12567">Systematic application of bed inclination of at least 30° to be monitored every 4 hours.</offsets></p></list-item><list-item><p><offsets xml_i="28006" xml_f="28101" txt_i="12568" txt_f="12663">Hand washing (hydroalcoholic friction) prior to any treatment and following isolation measures.</offsets></p></list-item><list-item><p><offsets xml_i="28131" xml_f="28205" txt_i="12664" txt_f="12738">Mouth care every 4–8 hours according to the protocol observed in the unit.</offsets></p></list-item><list-item><p><offsets xml_i="28235" xml_f="28327" txt_i="12739" txt_f="12831">Tracheal aspiration carried out using sterile equipment, only to be performed when required.</offsets></p></list-item><list-item><p><offsets xml_i="28357" xml_f="28402" txt_i="12832" txt_f="12877">Preferential oral insertion of feeding tubes.</offsets></p></list-item><list-item><p><offsets xml_i="28432" xml_f="28477" txt_i="12878" txt_f="12923">Starting enteral feeding as soon as possible.</offsets></p></list-item><list-item><p><offsets xml_i="28507" xml_f="28704" txt_i="12924" txt_f="13121">Systematic application of a glucose monitoring protocol in which the patient’s blood sugar level is measured every 4 hours, the objective being to maintain the glucose level between 4 and 8 mmol/L.</offsets></p></list-item><list-item><p><offsets xml_i="28734" xml_f="28836" txt_i="13122" txt_f="13224">Prophylactic antibiotic treatment limited to 48 hours for fractures operated within the first 6 hours.</offsets></p></list-item><list-item><p><offsets xml_i="28866" xml_f="29162" txt_i="13225" txt_f="13521">Curative antibiotic therapy reserved for infections for which the bacterial origin is documented, or probable, and in cases where other anti-infectious measures are insufficient, in accordance with the 2008 recommendations of the official French health authority on the proper use of antibiotics.</offsets><xref rid="R35" ref-type="bibr"><offsets xml_i="29194" xml_f="29196" txt_i="13521" txt_f="13523">35</offsets></xref><offsets xml_i="29203" xml_f="30177" txt_i="13523" txt_f="14497"> An adequate dosage regimen and method of antibiotic administration is provided to ensure an optimal concentration at the site of infection. Recourse to serum assay is useful whenever possible to avoid underdosing, which is a common cause of failure, as well as to avoid overdosing, which leads to iatrogenic pathologies. Narrow-spectrum antibiotics are preferred. In cases of severe infection, antibiotic treatment should be started as soon as possible following diagnostics and microbiological sampling, and started no later than the first hour in cases of septic shock. The duration of VAP treatment should be limited to 1 week, except in cases with non-fermenting Gram-negative bacterial infections for which antibiotic therapy should continue for 2 weeks to reduce the risk of recurrence. Antibiotic associations are strictly limited to precisely defined situations: the need to broaden the antibacterial spectrum; severe and microbiologically undocumented infections; </offsets><italic><offsets xml_i="30185" xml_f="30207" txt_i="14497" txt_f="14519">Pseudomonas aeruginosa</offsets></italic><offsets xml_i="30216" xml_f="30368" txt_i="14519" txt_f="14671"> infections and bacteria and antibiotic combinations associated with a high risk of resistance emergence. These include group 3 Enterobacteriaceae (eg, </offsets><italic><offsets xml_i="30376" xml_f="30388" txt_i="14671" txt_f="14683">Enterobacter</offsets></italic><offsets xml_i="30397" xml_f="30399" txt_i="14683" txt_f="14685">, </offsets><italic><offsets xml_i="30407" xml_f="30415" txt_i="14685" txt_f="14693">Serratia</offsets></italic><offsets xml_i="30424" xml_f="30426" txt_i="14693" txt_f="14695">, </offsets><italic><offsets xml_i="30434" xml_f="30454" txt_i="14695" txt_f="14715">Citrobacter freundii</offsets></italic><offsets xml_i="30463" xml_f="30465" txt_i="14715" txt_f="14717">, </offsets><italic><offsets xml_i="30473" xml_f="30484" txt_i="14717" txt_f="14728">Providencia</offsets></italic><offsets xml_i="30493" xml_f="30498" txt_i="14728" txt_f="14733"> and </offsets><italic><offsets xml_i="30506" xml_f="30516" txt_i="14733" txt_f="14743">Morganella</offsets></italic><offsets xml_i="30525" xml_f="30564" txt_i="14743" txt_f="14782">) and third-generation cephalosporins; </offsets><italic><offsets xml_i="30572" xml_f="30593" txt_i="14782" txt_f="14803">Staphylococcus aureus</offsets></italic><offsets xml_i="30602" xml_f="30803" txt_i="14803" txt_f="15004"> and fluoroquinolones, rifampicin, fusidic acid or fosfomycin and Enterobacteriaceae resistant to nalidixic acid and fluoroquinolones. Antibiotic therapy should be re-evaluated between 24 and 72 hours.</offsets></p></list-item><list-item><p><offsets xml_i="30833" xml_f="30870" txt_i="15005" txt_f="15042">Prevention of ulcer disease by anti-H</offsets><sub><offsets xml_i="30875" xml_f="30876" txt_i="15042" txt_f="15043">2</offsets></sub><offsets xml_i="30882" xml_f="30966" txt_i="15043" txt_f="15127"> and proton pump inhibitors, in accordance with the protocol observed in the centre.</offsets></p></list-item></list></p></sec><sec id="s2c"><title><offsets xml_i="31020" xml_f="31034" txt_i="15130" txt_f="15144">Study outcomes</offsets></title><sec id="s2c1"><title><offsets xml_i="31064" xml_f="31081" txt_i="15145" txt_f="15162">Primary end point</offsets></title><list list-type="bullet"><list-item><p><offsets xml_i="31128" xml_f="31250" txt_i="15163" txt_f="15285">Proportion of patients that develop VAP at day 28 in the ICU according to the American Thoracic Society (ATS) definition (</offsets><xref ref-type="boxed-text" rid="BX3"><offsets xml_i="31288" xml_f="31293" txt_i="15285" txt_f="15290">box 2</offsets></xref><offsets xml_i="31300" xml_f="31302" txt_i="15290" txt_f="15292">).</offsets><xref rid="R7" ref-type="bibr"><offsets xml_i="31333" xml_f="31334" txt_i="15292" txt_f="15293">7</offsets></xref></p></list-item></list><boxed-text id="BX3" position="float" orientation="portrait"><label><offsets xml_i="31432" xml_f="31437" txt_i="15294" txt_f="15299">Box 2</offsets></label><caption><title><offsets xml_i="31461" xml_f="31505" txt_i="15299" txt_f="15343">American Thoracic Society definition for VAP</offsets></title></caption><p><offsets xml_i="31526" xml_f="31632" txt_i="15344" txt_f="15450">VAP diagnosis is based on an association, 48 hours after the start of mechanical ventilation, of at least:</offsets></p><p><offsets xml_i="31639" xml_f="31678" txt_i="15451" txt_f="15490">Two clinical signs among the following:</offsets></p><list list-type="bullet"><list-item><p><offsets xml_i="31721" xml_f="31757" txt_i="15491" txt_f="15527">Fever ≥38.0°C or hypothermia ≤36.0°C</offsets></p></list-item><list-item><p><offsets xml_i="31787" xml_f="31820" txt_i="15528" txt_f="15561">Purulent endotracheal aspirations</offsets></p></list-item><list-item><p><offsets xml_i="31850" xml_f="31905" txt_i="15562" txt_f="15617">Hyperleucocytosis (≥12 000/mL) or leucopenia (≤4000/mL)</offsets></p></list-item></list><p><offsets xml_i="31931" xml_f="31961" txt_i="15618" txt_f="15648">One radiological sign such as:</offsets></p><list list-type="bullet"><list-item><p><offsets xml_i="32004" xml_f="32035" txt_i="15649" txt_f="15680">A new radiographic condensation</offsets></p></list-item><list-item><p><offsets xml_i="32065" xml_f="32128" txt_i="15681" txt_f="15744">Modification of a previously existing radiographic condensation</offsets></p></list-item></list><p><offsets xml_i="32154" xml_f="32239" txt_i="15745" txt_f="15830">And a positive bacterial analysis of the respiratory tract with cultures of at least:</offsets></p><list list-type="bullet"><list-item><p><offsets xml_i="32282" xml_f="32284" txt_i="15831" txt_f="15833">10</offsets><sup><offsets xml_i="32289" xml_f="32290" txt_i="15833" txt_f="15834">3</offsets></sup><offsets xml_i="32296" xml_f="32364" txt_i="15834" txt_f="15902"> CFU/mL for a brush by fibroscopy or blind protected distal sampling</offsets></p></list-item><list-item><p><offsets xml_i="32394" xml_f="32396" txt_i="15903" txt_f="15905">10</offsets><sup><offsets xml_i="32401" xml_f="32402" txt_i="15905" txt_f="15906">4</offsets></sup><offsets xml_i="32408" xml_f="32442" txt_i="15906" txt_f="15940"> CFU/mL for bronchoalveolar lavage</offsets></p></list-item><list-item><p><offsets xml_i="32472" xml_f="32474" txt_i="15941" txt_f="15943">10</offsets><sup><offsets xml_i="32479" xml_f="32480" txt_i="15943" txt_f="15944">6</offsets></sup><offsets xml_i="32486" xml_f="32516" txt_i="15944" txt_f="15974"> CFU/mL for tracheal aspirates</offsets></p></list-item></list><fn-group><fn id="BX3fn1"><p><offsets xml_i="32568" xml_f="32631" txt_i="15975" txt_f="16038">CFU, colony-forming unit; VAP, ventilator-associated pneumonia.</offsets></p></fn></fn-group></boxed-text></sec><sec id="s2c2"><title><offsets xml_i="32692" xml_f="32712" txt_i="16040" txt_f="16060">Secondary end points</offsets></title><list list-type="bullet"><list-item><p><offsets xml_i="32759" xml_f="32842" txt_i="16061" txt_f="16144">Proportion of patients that develop VAP in the ICU according to the ATS definition.</offsets><xref rid="R7" ref-type="bibr"><offsets xml_i="32873" xml_f="32874" txt_i="16144" txt_f="16145">7</offsets></xref></p></list-item><list-item><p><offsets xml_i="32911" xml_f="33570" txt_i="16146" txt_f="16805">Proportion of patients that develop bacteraemic VAP in the ICU according to the ATS definition. Bacteraemic VAP is defined as at least one positive blood culture that is not related to any other source of infection, and at least one positive respiratory sample culture obtained within 48 hours of each other. In addition, at least one of the microorganisms isolated in the respiratory sample needs to also be isolated in the blood cultures, whereas all isolates identified in the blood cultures (except for skin contaminants) should also grow in the simultaneously obtained respiratory sample in order to meet the complete definition of bacteraemic pneumonia.</offsets></p></list-item><list-item><p><offsets xml_i="33600" xml_f="33720" txt_i="16806" txt_f="16923">Proportion of patients that develop early (≤7 days) or late (&gt;7 days) VAP in the ICU according to the ATS definition.</offsets><xref rid="R7" ref-type="bibr"><offsets xml_i="33751" xml_f="33752" txt_i="16923" txt_f="16924">7</offsets></xref></p></list-item><list-item><p><offsets xml_i="33789" xml_f="33859" txt_i="16925" txt_f="16995">Time until the first diagnosis of VAP according to the ATS definition.</offsets><xref rid="R7" ref-type="bibr"><offsets xml_i="33890" xml_f="33891" txt_i="16995" txt_f="16996">7</offsets></xref></p></list-item><list-item><p><offsets xml_i="33928" xml_f="34077" txt_i="16997" txt_f="17146">Proportion of patients that develop ventilator-associated events (VAE) according to the Centers for Disease Control and Prevention (CDC) definition (</offsets><xref ref-type="table" rid="T1"><offsets xml_i="34109" xml_f="34116" txt_i="17146" txt_f="17153">table 1</offsets></xref><offsets xml_i="34123" xml_f="34125" txt_i="17153" txt_f="17155">).</offsets><xref rid="R36" ref-type="bibr"><offsets xml_i="34157" xml_f="34159" txt_i="17155" txt_f="17157">36</offsets></xref></p></list-item><list-item><p><offsets xml_i="34196" xml_f="34227" txt_i="17158" txt_f="17189">Number of ventilator-free days.</offsets></p></list-item><list-item><p><offsets xml_i="34257" xml_f="34288" txt_i="17190" txt_f="17221">Number of antibiotic-free days.</offsets></p></list-item><list-item><p><offsets xml_i="34318" xml_f="34344" txt_i="17222" txt_f="17248">Length of stay in the ICU.</offsets></p></list-item><list-item><p><offsets xml_i="34374" xml_f="34428" txt_i="17249" txt_f="17303">Proportion of patients that die during their ICU stay.</offsets></p></list-item><list-item><p><offsets xml_i="34458" xml_f="34568" txt_i="17304" txt_f="17414">Proportion of patients that require corticosteroids or bronchodilators within 48 hours of tracheal extubation.</offsets></p></list-item></list><table-wrap id="T1" orientation="portrait" position="float"><label><offsets xml_i="34658" xml_f="34665" txt_i="17415" txt_f="17422">Table 1</offsets></label><caption><p><offsets xml_i="34685" xml_f="34773" txt_i="17422" txt_f="17510">The Centers for Diseases Control’s modified definitions for ventilator-associated events</offsets><xref rid="R36" ref-type="bibr"><offsets xml_i="34805" xml_f="34807" txt_i="17510" txt_f="17512">36</offsets></xref></p></caption><table frame="hsides" rules="groups"><tbody><tr><td valign="top" align="left" rowspan="1" colspan="1"><offsets xml_i="34930" xml_f="34959" txt_i="17513" txt_f="17542">New respiratory deterioration</offsets></td><td valign="top" align="left" rowspan="1" colspan="1"><offsets xml_i="35018" xml_f="35055" txt_i="17543" txt_f="17580">Ventilator-associated condition (VAC)</offsets></td><td valign="top" align="left" rowspan="1" colspan="1"><offsets xml_i="35114" xml_f="35443" txt_i="17581" txt_f="17907">≥2 calendar days of stable or decreasing daily minimum positive end-expiratory pressure or daily minimum fraction of inspired oxygen, followed by a rise in daily minimum positive end-expiratory pressure of ≥3 cm of water or a rise in the daily minimum percentage of inspired oxygen by &gt;20 points sustained for ≥2 calendar days</offsets></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><offsets xml_i="35511" xml_f="35567" txt_i="17908" txt_f="17964">New respiratory deterioration with evidence of infection</offsets></td><td valign="top" align="left" rowspan="1" colspan="1"><offsets xml_i="35626" xml_f="35685" txt_i="17965" txt_f="18024">Infection-related ventilator-associated complication (IVAC)</offsets></td><td valign="top" align="left" rowspan="1" colspan="1"><offsets xml_i="35744" xml_f="35748" txt_i="18025" txt_f="18029">VAC </offsets><break></break><offsets xml_i="35763" xml_f="35851" txt_i="18029" txt_f="18117">AND a temperature of 38°C or a leucocyte count of ≤4000 or ≥12 000 per cubic millimetre </offsets><break></break><offsets xml_i="35866" xml_f="36037" txt_i="18117" txt_f="18288">AND one or more new antibiotics continued for at least 4 days within two calendar days before or after onset of a VAC, excluding the first 2 days of mechanical ventilation</offsets></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><offsets xml_i="36105" xml_f="36180" txt_i="18289" txt_f="18364">New respiratory deterioration with possible evidence of pulmonary infection</offsets></td><td valign="top" align="left" rowspan="1" colspan="1"><offsets xml_i="36239" xml_f="36279" txt_i="18365" txt_f="18405">Possible ventilator-associated pneumonia</offsets></td><td valign="top" align="left" rowspan="1" colspan="1"><offsets xml_i="36338" xml_f="36343" txt_i="18406" txt_f="18411">IVAC </offsets><break></break><offsets xml_i="36358" xml_f="36393" txt_i="18411" txt_f="18446">AND one of the following criteria: </offsets><break></break><offsets xml_i="36408" xml_f="36608" txt_i="18446" txt_f="18646">Criterion 1: positive culture of one of the following specimens, meeting quantitative or semi-quantitative thresholds as outlined in protocol, without requirement for purulent respiratory secretions: </offsets><break></break><offsets xml_i="36623" xml_f="36624" txt_i="18646" txt_f="18647">
</offsets><list list-type="bullet"><list-item><p><offsets xml_i="36663" xml_f="36688" txt_i="18647" txt_f="18672">Endotracheal aspirate ≥10</offsets><sup><offsets xml_i="36693" xml_f="36694" txt_i="18672" txt_f="18673">5</offsets></sup><offsets xml_i="36700" xml_f="36749" txt_i="18673" txt_f="18722"> CFU/mL or corresponding semi-quantitative result</offsets></p></list-item><list-item><p><offsets xml_i="36779" xml_f="36805" txt_i="18723" txt_f="18749">Bronchoalveolar lavage,≥10</offsets><sup><offsets xml_i="36810" xml_f="36811" txt_i="18749" txt_f="18750">4</offsets></sup><offsets xml_i="36817" xml_f="36866" txt_i="18750" txt_f="18799"> CFU/mL or corresponding semi-quantitative result</offsets></p></list-item><list-item><p><offsets xml_i="36896" xml_f="36911" txt_i="18800" txt_f="18815">Lung tissue,≥10</offsets><sup><offsets xml_i="36916" xml_f="36917" txt_i="18815" txt_f="18816">4</offsets></sup><offsets xml_i="36923" xml_f="36972" txt_i="18816" txt_f="18865"> CFU/mL or corresponding semi-quantitative result</offsets></p></list-item><list-item><p><offsets xml_i="37002" xml_f="37030" txt_i="18866" txt_f="18894">Protected specimen brush,≥10</offsets><sup><offsets xml_i="37035" xml_f="37036" txt_i="18894" txt_f="18895">3</offsets></sup><offsets xml_i="37042" xml_f="37091" txt_i="18895" txt_f="18944"> CFU/mL or corresponding semi-quantitative result</offsets></p></list-item></list><offsets xml_i="37114" xml_f="37502" txt_i="18945" txt_f="19327">Criterion 2: purulent respiratory secretions (defined as secretions from the lungs, bronchi or trachea that contain&gt;25 neutrophils and &lt;10 squamous epithelial cells per low power field (lpf, x100)) plus organism identified from one of the following specimens (to include qualitative culture, or quantitative/semi-quantitative culture without sufficient growth to meet criterion #1):</offsets><list list-type="bullet"><list-item><p><offsets xml_i="37541" xml_f="37547" txt_i="19327" txt_f="19333">Sputum</offsets></p></list-item><list-item><p><offsets xml_i="37577" xml_f="37598" txt_i="19334" txt_f="19355">Endotracheal aspirate</offsets></p></list-item><list-item><p><offsets xml_i="37628" xml_f="37650" txt_i="19356" txt_f="19378">Bronchoalveolar lavage</offsets></p></list-item><list-item><p><offsets xml_i="37680" xml_f="37691" txt_i="19379" txt_f="19390">Lung tissue</offsets></p></list-item><list-item><p><offsets xml_i="37721" xml_f="37745" txt_i="19391" txt_f="19415">Protected specimen brush</offsets></p></list-item><list-item><p><offsets xml_i="37775" xml_f="37824" txt_i="19416" txt_f="19465">Criterion 3: one of the following positive tests:</offsets></p></list-item><list-item><p><offsets xml_i="37854" xml_f="37977" txt_i="19466" txt_f="19589">Organism identified from pleural fluid (where specimen was obtained during thoracentesis or initial placement of chest tube</offsets></p></list-item><list-item><p><offsets xml_i="38007" xml_f="38045" txt_i="19590" txt_f="19628">and NOT from an indwelling chest tube)</offsets></p></list-item><list-item><p><offsets xml_i="38075" xml_f="38465" txt_i="19629" txt_f="20019">Lung histopathology, defined as: 1) abscess formation or foci of consolidation with intense neutrophil accumulation in bronchioles and alveoli; 2) evidence of lung parenchyma invasion by fungi (hyphae, pseudohyphae or yeast forms); 3) evidence of infection with the viral pathogens listed below based on results of immunohistochemical assays, cytology or microscopy performed on lung tissue</offsets></p></list-item><list-item><p><offsets xml_i="38495" xml_f="38515" txt_i="20020" txt_f="20040">Diagnostic test for </offsets><italic><offsets xml_i="38523" xml_f="38533" txt_i="20040" txt_f="20050">Legionella</offsets></italic><offsets xml_i="38542" xml_f="38550" txt_i="20050" txt_f="20058"> species</offsets></p></list-item><list-item><p><offsets xml_i="38580" xml_f="38751" txt_i="20059" txt_f="20230">Diagnostic test on respiratory secretions for influenza virus, respiratory syncytial virus, adenovirus, parainfluenza virus, rhinovirus, human metapneumovirus, coronavirus</offsets></p></list-item></list><offsets xml_i="38774" xml_f="38775" txt_i="20231" txt_f="20232">
</offsets></td></tr></tbody></table></table-wrap><p><offsets xml_i="38817" xml_f="39003" txt_i="20233" txt_f="20419">Attempted detection of VAP signs will be performed on a daily basis while the patient is being mechanically ventilated, in accordance with the definition established by the ATS in 2005 (</offsets><xref ref-type="boxed-text" rid="BX3"><offsets xml_i="39041" xml_f="39046" txt_i="20419" txt_f="20424">box 2</offsets></xref><offsets xml_i="39053" xml_f="39055" txt_i="20424" txt_f="20426">).</offsets><xref rid="R7" ref-type="bibr"><offsets xml_i="39086" xml_f="39087" txt_i="20426" txt_f="20427">7</offsets></xref><offsets xml_i="39094" xml_f="39420" txt_i="20427" txt_f="20753"> A thoracic X-ray aimed at detecting VAP is to be carried out within a few hours whenever at least two of the following clinical signs of VAP are observed in the same clinical examination: fever ≥38.0°C or hypothermia ≤36.0°C, purulent endotracheal secretions or either hyperleucocytosis (≥12 000/mL) or leucopenia (≤4000/mL).</offsets></p><p><offsets xml_i="39427" xml_f="39615" txt_i="20754" txt_f="20942">Whenever the patient meets the clinical and radiological criteria on the same day, VAP is suspected and the modified clinical pulmonary infection score will be calculated, as presented in </offsets><xref ref-type="table" rid="T2"><offsets xml_i="39647" xml_f="39654" txt_i="20942" txt_f="20949">table 2</offsets></xref><offsets xml_i="39661" xml_f="39959" txt_i="20949" txt_f="21244">. Bacterial analysis of the respiratory tract will be carried out especially if the calculated score is &gt;6. The type of sampling (bronchoalveolar lavage, blind distal sampling or tracheal aspirates) is left to the discretion of the attending physician, and depends on the procedures of the unit.</offsets></p><table-wrap id="T2" orientation="portrait" position="float"><label><offsets xml_i="40030" xml_f="40037" txt_i="21245" txt_f="21252">Table 2</offsets></label><caption><p><offsets xml_i="40057" xml_f="40140" txt_i="21252" txt_f="21335">The modified clinical pulmonary infection score for ventilator-associated pneumonia</offsets><xref rid="R7" ref-type="bibr"><offsets xml_i="40171" xml_f="40172" txt_i="21335" txt_f="21336">7</offsets></xref><offsets xml_i="40179" xml_f="40222" txt_i="21336" txt_f="21379"> ARDS, acute respiratory distress syndrome.</offsets></p></caption><table frame="hsides" rules="groups"><tbody><tr><td valign="top" align="left" rowspan="1" colspan="1"><offsets xml_i="40338" xml_f="40354" txt_i="21380" txt_f="21396">Temperature (°C)</offsets></td><td valign="top" align="char" char="." rowspan="1" colspan="1"></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><offsets xml_i="40490" xml_f="40506" txt_i="21398" txt_f="21414"> ≥36.5 and ≤38.4</offsets></td><td valign="top" align="char" char="." rowspan="1" colspan="1"><offsets xml_i="40574" xml_f="40575" txt_i="21415" txt_f="21416">0</offsets></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><offsets xml_i="40643" xml_f="40659" txt_i="21417" txt_f="21433"> ≥38.5 and ≤38.9</offsets></td><td valign="top" align="char" char="." rowspan="1" colspan="1"><offsets xml_i="40727" xml_f="40728" txt_i="21434" txt_f="21435">1</offsets></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><offsets xml_i="40796" xml_f="40811" txt_i="21436" txt_f="21451"> ≥39.0 or ≤36.0</offsets></td><td valign="top" align="char" char="." rowspan="1" colspan="1"><offsets xml_i="40879" xml_f="40880" txt_i="21452" txt_f="21453">2</offsets></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><offsets xml_i="40948" xml_f="40964" txt_i="21454" txt_f="21470">Leucocytes (g/L)</offsets></td><td valign="top" align="char" char="." rowspan="1" colspan="1"></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><offsets xml_i="41100" xml_f="41111" txt_i="21472" txt_f="21483"> ≥4 and ≤11</offsets></td><td valign="top" align="char" char="." rowspan="1" colspan="1"><offsets xml_i="41179" xml_f="41180" txt_i="21484" txt_f="21485">0</offsets></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><offsets xml_i="41248" xml_f="41264" txt_i="21486" txt_f="21496"> &lt;4 or &gt;11</offsets></td><td valign="top" align="char" char="." rowspan="1" colspan="1"><offsets xml_i="41332" xml_f="41333" txt_i="21497" txt_f="21498">1</offsets></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><offsets xml_i="41401" xml_f="41428" txt_i="21499" txt_f="21526">Tracheal secretion quantity</offsets></td><td valign="top" align="char" char="." rowspan="1" colspan="1"></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><offsets xml_i="41564" xml_f="41568" txt_i="21528" txt_f="21532"> Low</offsets></td><td valign="top" align="char" char="." rowspan="1" colspan="1"><offsets xml_i="41636" xml_f="41637" txt_i="21533" txt_f="21534">0</offsets></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><offsets xml_i="41705" xml_f="41714" txt_i="21535" txt_f="21544"> Moderate</offsets></td><td valign="top" align="char" char="." rowspan="1" colspan="1"><offsets xml_i="41782" xml_f="41783" txt_i="21545" txt_f="21546">1</offsets></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><offsets xml_i="41851" xml_f="41860" txt_i="21547" txt_f="21556"> Abundant</offsets></td><td valign="top" align="char" char="." rowspan="1" colspan="1"><offsets xml_i="41928" xml_f="41929" txt_i="21557" txt_f="21558">2</offsets></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><offsets xml_i="41997" xml_f="42022" txt_i="21559" txt_f="21584">Tracheal secretion aspect</offsets></td><td valign="top" align="left" rowspan="1" colspan="1"></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><offsets xml_i="42149" xml_f="42158" txt_i="21586" txt_f="21595"> Purulent</offsets></td><td valign="top" align="left" rowspan="1" colspan="1"><offsets xml_i="42217" xml_f="42219" txt_i="21596" txt_f="21598">+1</offsets></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><offsets xml_i="42287" xml_f="42290" txt_i="21599" txt_f="21602">PaO</offsets><sub><offsets xml_i="42295" xml_f="42296" txt_i="21602" txt_f="21603">2</offsets></sub><offsets xml_i="42302" xml_f="42306" txt_i="21603" txt_f="21607">/FiO</offsets><sub><offsets xml_i="42311" xml_f="42312" txt_i="21607" txt_f="21608">2</offsets></sub><offsets xml_i="42318" xml_f="42319" txt_i="21608" txt_f="21609">
</offsets></td><td valign="top" align="char" char="." rowspan="1" colspan="1"></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><offsets xml_i="42455" xml_f="42471" txt_i="21611" txt_f="21624"> &gt;240 or ARDS</offsets></td><td valign="top" align="char" char="." rowspan="1" colspan="1"><offsets xml_i="42539" xml_f="42540" txt_i="21625" txt_f="21626">0</offsets></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><offsets xml_i="42608" xml_f="42633" txt_i="21627" txt_f="21652"> ≤240 and absence of ARDS</offsets></td><td valign="top" align="char" char="." rowspan="1" colspan="1"><offsets xml_i="42701" xml_f="42702" txt_i="21653" txt_f="21654">2</offsets></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><offsets xml_i="42770" xml_f="42794" txt_i="21655" txt_f="21679">Frontal chest radiograph</offsets></td><td valign="top" align="char" char="." rowspan="1" colspan="1"></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><offsets xml_i="42930" xml_f="42944" txt_i="21681" txt_f="21695"> No infiltrate</offsets></td><td valign="top" align="char" char="." rowspan="1" colspan="1"><offsets xml_i="43012" xml_f="43013" txt_i="21696" txt_f="21697">0</offsets></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><offsets xml_i="43081" xml_f="43122" txt_i="21698" txt_f="21739"> Diffuse and/or heterogeneous infiltrates</offsets></td><td valign="top" align="char" char="." rowspan="1" colspan="1"><offsets xml_i="43190" xml_f="43191" txt_i="21740" txt_f="21741">1</offsets></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><offsets xml_i="43259" xml_f="43280" txt_i="21742" txt_f="21763"> Localised infiltrate</offsets></td><td valign="top" align="char" char="." rowspan="1" colspan="1"><offsets xml_i="43348" xml_f="43349" txt_i="21764" txt_f="21765">2</offsets></td></tr></tbody></table></table-wrap><p><offsets xml_i="43391" xml_f="43579" txt_i="21766" txt_f="21954">When a patient is suspected to have developed VAP, two assessors masked to the group assignment will review the case-report form and classify the case according to the accepted definition.</offsets></p></sec></sec><sec id="s2d"><title><offsets xml_i="43616" xml_f="43636" txt_i="21957" txt_f="21977">Participant timeline</offsets></title><p><offsets xml_i="43647" xml_f="43895" txt_i="21978" txt_f="22226">The patients will be monitored from randomisation through to their discharge from the ICU without exceeding 60 days following inclusion. Evaluation of the assessment criteria will be carried out depending on the duration of patient stay in the ICU.</offsets><list list-type="bullet"><list-item><p><offsets xml_i="43934" xml_f="44036" txt_i="22226" txt_f="22325">Evaluation will be carried out on discharge from the ICU for patients with an ICU stay of &lt;28 days.</offsets></p></list-item><list-item><p><offsets xml_i="44066" xml_f="44191" txt_i="22326" txt_f="22448">Evaluations will be carried out on day 28 and on discharge from the ICU for patients with an ICU stay of ≥28 but &lt;60 days.</offsets></p></list-item><list-item><p><offsets xml_i="44221" xml_f="44313" txt_i="22449" txt_f="22541">Evaluations will be carried out on days 28 and 60 for patients with an ICU stay of ≥60 days.</offsets></p></list-item></list></p><p><offsets xml_i="44343" xml_f="44625" txt_i="22543" txt_f="22825">Any patient who leaves the ICU will be considered to have exited the study. Any readmission into the ICU (even within 60 days following the trauma) will not be taken into account. Any event that occurs after the first ICU discharge will not be considered in the assessment criteria.</offsets></p><p><offsets xml_i="44632" xml_f="44841" txt_i="22826" txt_f="23035">Any patient can exit the study if he or she wishes, without having to provide justification. The quality of their care will not be altered, and the outcome will not be taken into account in the final analysis.</offsets></p></sec><sec id="s2e"><title><offsets xml_i="44872" xml_f="44895" txt_i="23037" txt_f="23060">Sample size calculation</offsets></title><p><offsets xml_i="44906" xml_f="45353" txt_i="23061" txt_f="23508">The number of participants (n=220 in each group) is based on an estimation of VAP incidence of 20% of patients in the control group and a reduced VAP incidence (halved) in the intervention group, with a study power of 80% and p value of 5% in bilateral situation. The VAP incidence in the control group was chosen on the basis of an unpublished analysis of the database of AtlanRéa, a French research network devoted to studies on trauma patients.</offsets><xref rid="R37" ref-type="bibr"><offsets xml_i="45385" xml_f="45390" txt_i="23508" txt_f="23513">37 38</offsets></xref></p><p><offsets xml_i="45404" xml_f="45609" txt_i="23514" txt_f="23719">Given the recruitment potential of the centres approached to participate in the study, together with the constraints associated with the protocol, the expected inclusion duration has been set at 33 months.</offsets></p></sec><sec id="s2f"><title><offsets xml_i="45640" xml_f="45651" txt_i="23721" txt_f="23732">Recruitment</offsets></title><p><offsets xml_i="45662" xml_f="45847" txt_i="23733" txt_f="23918">Patients admitted into the ICUs of 15 French University Hospitals will be screened and enrolled within 24 hours of trauma. Patient enrolment will be decided by the attending physicians.</offsets></p></sec><sec id="s2g"><title><offsets xml_i="45878" xml_f="45926" txt_i="23920" txt_f="23968">Assignment of interventions and masking protocol</offsets></title><p><offsets xml_i="45937" xml_f="46862" txt_i="23969" txt_f="24888">A computer-generated numbered list was provided by a statistician not involved in either screening patients or the assessment of outcomes. Randomisation will be carried out using a secure web-based randomisation system with stratification by centre and severity of unconsciousness at the time of inclusion (Glasgow Coma Scale &lt;8 or ≥8), to account for differences in patient treatment between centres and the heightened VAP risk in patients with a Glasgow Coma Scale &lt;8. Patients will be randomly assigned (1:1) into one of the two treatment groups, based on the method used to monitor tracheal cuff pressure. Masking of the participants and ICU staff will not be feasible due to the nature of the device, which is placed closed to the patient’s face. However, the microbiologists that test the pulmonary and blood samples, the outcome assessors (NM and OM) and the statisticians will be masked to the group assignment.</offsets></p></sec><sec id="s2h"><title><offsets xml_i="46893" xml_f="46967" txt_i="24890" txt_f="24964">Data collection, confidentiality, storage and archiving of study documents</offsets></title><p><offsets xml_i="46978" xml_f="47579" txt_i="24965" txt_f="25566">Independent clinical research assistants are available at each participating hospital to help with running the study and data collection. Study documents will be de-identified and stored for 15 years, as per the protocol for non-clinical trial notification (CTN) interventional studies. Data will be electronically stored on double password-protected computers. Hard copies of data (clinical research files) will be stored in a locked, secure office. All personnel involved in data analysis will be masked. Only the principal investigators and the statisticians will have access to the final data set.</offsets></p></sec><sec id="s2i"><title><offsets xml_i="47610" xml_f="47629" txt_i="25568" txt_f="25587">Statistical methods</offsets></title><p><offsets xml_i="47640" xml_f="48026" txt_i="25588" txt_f="25971">Analyses will be performed following the intention-to-treat principle (all randomised patients except those that withdrew consent). Statistical analyses will take into account the stratified randomisation (centre and Glasgow Coma Scale &lt;8 or ≥8), as recommended in the 2010 Consolidated Standards of Reporting Trials (CONSORT) guidelines and other studies reported in the literature.</offsets><xref rid="R39" ref-type="bibr"><offsets xml_i="48058" xml_f="48063" txt_i="25971" txt_f="25976">39 40</offsets></xref></p><p><offsets xml_i="48077" xml_f="48313" txt_i="25977" txt_f="26213">The categorical variables will be reported as numbers and percentages, while continuous variables will be summarised using means (±SD) or medians (IQR) for normally and non-normally distributed data, along with their respective 95% CIs.</offsets></p><p><offsets xml_i="48320" xml_f="48531" txt_i="26214" txt_f="26425">Analyses of the primary end point and secondary end points related to VAP incidence will use logistic regression models adjusted for stratification factors and covariates significantly imbalanced between groups.</offsets></p><p><offsets xml_i="48538" xml_f="48650" txt_i="26426" txt_f="26538">The cumulative event curves (time until first VAP diagnosis) will be estimated using the Kaplan-Meier procedure.</offsets></p><p><offsets xml_i="48657" xml_f="49148" txt_i="26539" txt_f="27030">The number of ventilator-free days (VFD) is the number of days for which the patient is successfully weaned from mechanical ventilation until the end point at day 28 (or day 60). This is defined as follows: VFD=0 for patients who died within 28 (or 60) days or required mechanical ventilation for 28 (or 60) or more days; VFDs=(28 (or 60)−x) for patients who were successfully weaned off mechanical ventilation within 28 (or 60) days, where x is the number of days on mechanical ventilation.</offsets></p><p><offsets xml_i="49155" xml_f="49385" txt_i="27031" txt_f="27261">The number of antibiotic-free days (AFD) is the number of days that the living patient did not receive antibiotics over 28 (or 60) days. Any prophylactic or curative antibiotic therapy related to the trauma will not be considered.</offsets></p><p><offsets xml_i="49392" xml_f="49732" txt_i="27262" txt_f="27602">The VFD and AFD will be assessed in the same manner, and will be compared between groups using regression models that allow adjustment for stratification factors. The other categorical secondary end points will be compared between groups using logistic regression models. Statistical analyses will all be conducted using SAS V.9.3 software.</offsets></p><p><offsets xml_i="49739" xml_f="50176" txt_i="27603" txt_f="28040">Missing data will be described as the number and corresponding percentage for each group. The presence of any imbalance in the proportion of missing data between treatment groups will be evaluated using logistic regression models. To assess the robustness of the results in the case of missing data, sensitivity analyses will be performed with imputation of missing data (worst value such as failure, death, etc) and multiple imputation.</offsets></p></sec><sec id="s2j"><title><offsets xml_i="50207" xml_f="50217" txt_i="28042" txt_f="28052">Monitoring</offsets></title><p><offsets xml_i="50228" xml_f="50674" txt_i="28053" txt_f="28499">Clinical research associates will ensure that patient inclusion, data collection, registry and rapport are in line with the protocol, and that the study is conducted in accordance with the Good Clinical Practice guidelines. Furthermore, he or she will verify the following variables: patient initials, date of birth, sex, signed consent form, eligibility criteria, date of randomisation, treatment assignment, adverse events and study end points.</offsets></p></sec></sec><sec id="s3"><title><offsets xml_i="50710" xml_f="50734" txt_i="28502" txt_f="28526">Ethics and dissemination</offsets></title><sec id="s3a"><title><offsets xml_i="50763" xml_f="50787" txt_i="28527" txt_f="28551">Research ethics approval</offsets></title><p><offsets xml_i="50798" xml_f="51499" txt_i="28552" txt_f="29253">The clinical trial will be carried out in line with the principles of the Declaration of Helsinki and according to the Clinical Trials Directive 2001/20/EC of the European Parliament on the approximation of the laws, regulations and administrative provisions of the Member States relating to the implementation of Good Clinical Practices in the conduct of clinical trials on medicinal products for human use. Ethical aspects of this research project have been approved by the ethics committee of Poitiers University Hospital (France). The ethics committee of Poitiers approval cover all participant sites. The trial will be monitored by the research monitoring officer of Poitiers University Hospital.</offsets></p></sec><sec id="s3b"><title><offsets xml_i="51530" xml_f="51537" txt_i="29255" txt_f="29262">Consent</offsets></title><p><offsets xml_i="51548" xml_f="52158" txt_i="29263" txt_f="29873">Prior consent of the subject will not be possible; therefore, consent of the subject’s legally acceptable representative will be requested. A consent form specifically designed for the subject’s legally acceptable representative will be provided with documented approval or favourable opinion of the institutional review board in order to protect the rights, safety and well-being of the subject and to ensure compliance with any applicable regulatory requirements. Non-objection to participation in the study by the patient’s relatives will be solicited, according to the requirements of the ethics committee.</offsets></p></sec><sec id="s3c"><title><offsets xml_i="52189" xml_f="52204" txt_i="29875" txt_f="29890">Confidentiality</offsets></title><p><offsets xml_i="52215" xml_f="52436" txt_i="29891" txt_f="30112">People with direct access to the data will take all necessary precautions to maintain confidentiality. All data collected during the study will be rendered anonymous. Only initials and inclusion number will be registered.</offsets></p></sec><sec id="s3d"><title><offsets xml_i="52467" xml_f="52487" txt_i="30114" txt_f="30134">Dissemination policy</offsets></title><p><offsets xml_i="52498" xml_f="52760" txt_i="30135" txt_f="30397">The results of the study will be released to the participating physicians, referring physicians and medical community no later than 1 year after the completion of the trial, through presentation at scientific conferences and publication in peer-reviewed journals</offsets></p></sec></sec><sec sec-type="discussion" id="s4"><title><offsets xml_i="52818" xml_f="52828" txt_i="30400" txt_f="30410">Discussion</offsets></title><p><offsets xml_i="52839" xml_f="53474" txt_i="30411" txt_f="31046">To the best of our knowledge, this is the first large-scale study to evaluate the usefulness of continuous pneumatic regulation of tracheal cuff pressure in a population of severe trauma patients, who will also benefit from other recommended VAP preventive measures. At an individual level, the benefits are expected to include reduced duration of mechanical ventilation and stay in the ICU, as well as improved patient prognosis. At a collective level, a lower cost of hospital stay is expected, in addition to fewer days on antibiotics, associated with a reduction in the selective pressure perpetuating multidrug-resistant bacteria.</offsets></p><p><offsets xml_i="53481" xml_f="54092" txt_i="31047" txt_f="31658">In order to keep management practices as standardised as possible, we decided to limit the number of investigating centres to 15 university hospital centres (CHU), all of which are recognised in the field of trauma care and treat more than 50 severe trauma patients per year. These centres belong to three networks that share the common objective of promoting multicentre clinical research, consisting of AtlanRéa (Grand Ouest surgical intensive care network), AzuRéa (Grand Sud intensive care network) and TraumaBase (APHP trauma intensive care network). These 15 centres also share the same standards of care.</offsets></p><p><offsets xml_i="54099" xml_f="54274" txt_i="31659" txt_f="31834">Previous studies that have evaluated devices aimed to continuously regulate tracheal cuff pressure have reported that these devices are efficient in controlling cuff pressure,</offsets><xref rid="R41" ref-type="bibr"><offsets xml_i="54306" xml_f="54308" txt_i="31834" txt_f="31836">41</offsets></xref><offsets xml_i="54315" xml_f="54351" txt_i="31836" txt_f="31872"> and are well-tolerated by patients.</offsets><xref rid="R33" ref-type="bibr"><offsets xml_i="54383" xml_f="54385" txt_i="31872" txt_f="31874">33</offsets></xref><offsets xml_i="54392" xml_f="54502" txt_i="31874" txt_f="31984"> In this setting, the choice of a pneumatic device instead of an electronic device presents several advantages</offsets><xref rid="R33" ref-type="bibr"><offsets xml_i="54534" xml_f="54536" txt_i="31984" txt_f="31986">33</offsets></xref><offsets xml_i="54543" xml_f="54918" txt_i="31986" txt_f="32361">: better reactivity with fewer periods of insufficient or excessive pressure into the tracheal cuff, and consequently, reduced risk of microinhalations and tracheal lesions; no need for an electricity supply; low acquisition cost and ease of use. Finally, the encouraging preliminary results previously reported using this device also significantly contributed to our choice.</offsets><xref rid="R27" ref-type="bibr"><offsets xml_i="54950" xml_f="54952" txt_i="32361" txt_f="32363">27</offsets></xref></p><p><offsets xml_i="54966" xml_f="55607" txt_i="32364" txt_f="33005">In the present study, no additional risk will be incurred by the study participants in terms of the usual therapy received during their hospital stay. Patients will be cared for as usual by their attending physicians. No supplementary examination will be imposed by the protocol. As the patient will be unable to hear the given information, information regarding the study will be delivered to his or her close relatives or friends. In accordance with the directives of the French national commission for data protection and liberties, the patient will be afforded the possibility of objecting to the use of data gathered in his or her name.</offsets></p><sec id="s4a"><title><offsets xml_i="55632" xml_f="55649" txt_i="33006" txt_f="33023">Study limitations</offsets></title><p><offsets xml_i="55660" xml_f="55820" txt_i="33024" txt_f="33184">The incidence of VAP is the primary end point of this trial; however, VAP diagnosis may be difficult to perform in the ICU. Several criteria have been proposed,</offsets><xref rid="R7" ref-type="bibr"><offsets xml_i="55851" xml_f="55861" txt_i="33184" txt_f="33194">7 36 42–44</offsets></xref><offsets xml_i="55868" xml_f="55910" txt_i="33194" txt_f="33236"> but their reported performances are poor.</offsets><xref rid="R45" ref-type="bibr"><offsets xml_i="55942" xml_f="55944" txt_i="33236" txt_f="33238">45</offsets></xref><offsets xml_i="55951" xml_f="56035" txt_i="33238" txt_f="33322"> In this trial, VAP incidence will be determined according to the 2005 ATS criteria.</offsets><xref rid="R7" ref-type="bibr"><offsets xml_i="56066" xml_f="56067" txt_i="33322" txt_f="33323">7</offsets></xref><offsets xml_i="56074" xml_f="56247" txt_i="33323" txt_f="33496"> This choice could be challenged; however, these criteria have been commonly used for VAP diagnosis in the literature. We will also record VAE according to the CDC criteria,</offsets><xref rid="R36" ref-type="bibr"><offsets xml_i="56279" xml_f="56281" txt_i="33496" txt_f="33498">36</offsets></xref><offsets xml_i="56288" xml_f="56573" txt_i="33498" txt_f="33783"> and compare the ATS and CDC definitions for VAP as a secondary objective. The halving of VAP rate could seems ambitious for a single intervention. However, such a finding was reported in two previous studies assessing the clinical impact of continuous control device of cuff pressure.</offsets><xref rid="R46" ref-type="bibr"><offsets xml_i="56605" xml_f="56610" txt_i="33783" txt_f="33788">46 47</offsets></xref></p><p><offsets xml_i="56624" xml_f="56934" txt_i="33789" txt_f="34099">Because, mouth care and stress ulcer prophylaxis are based on local written protocols, they may act as potential confounding variables. However, this will be controlled by the stratification of the randomisation at the centre level and adjustment of statistical analyses in cases of differences between groups.</offsets></p><p><offsets xml_i="56941" xml_f="57128" txt_i="34100" txt_f="34287">Finally, masking is not feasible due to the nature of the intervention. However, the end points will be assessed by two assessors masked to the group assignment in order to minimise bias.</offsets></p><p><offsets xml_i="57135" xml_f="57395" txt_i="34288" txt_f="34548">In conclusion, this trial is the first multicentre randomised controlled open-label study adequately powered to test the hypothesis that a continuous pneumatic regulation of tracheal cuff pressure prevents VAP in mechanically ventilated severe trauma patients.</offsets></p></sec><sec id="s4b"><title><offsets xml_i="57426" xml_f="57447" txt_i="34550" txt_f="34571">Participating centres</offsets></title><p><offsets xml_i="57458" xml_f="58387" txt_i="34572" txt_f="35501">University Hospital of Poitiers (Professor Olivier Mimoz), University Hospital of Angers (Professor Sigismond Lasocki), University Hospital of Beaujon (Professor Catherine Paugam), University Hospital of Bicêtre (Professor Jacques Durnteau), University Hospital of Clermont-Ferrand (Professor Jean-Michel Constantin), University Hospital of Grenoble (Professor Jean-François Payen), University Hospital of Marseille (Professor Marc Leone), University Hospital of Nantes (Professor Karim Asehnoune), University Hospital of Nice (Professor Carole Ichai), University Hospital of Nîmes (Professor Jean-Yves Lefrant), University Hospital of Rouen (Professor Benoit Veber), University Hospital of Strasbourg (Professor Julien Pottecher), University Hospital of Besançon (Professor Sébastien Pili-Floury), University Hospital of Dijon (Professor Belaid Bouhemad), University Hospital of Nancy (Professor Gérard Audibert); all in France.</offsets></p></sec><sec id="s4c"><title><offsets xml_i="58418" xml_f="58430" txt_i="35503" txt_f="35515">Trial status</offsets></title><p><offsets xml_i="58441" xml_f="58756" txt_i="35516" txt_f="35831">The trial is currently in progress, and the inclusion process started in July 2015. At the time of manuscript submission, 229 patients had been included. The first patient was included 2 days after registration of the study on ClinicalTrials.gov. We estimate that the last patient will be recruited in January 2018.</offsets></p></sec></sec><sec sec-type="supplementary-material"><title><offsets xml_i="58818" xml_f="58840" txt_i="35834" txt_f="35856">Supplementary Material</offsets></title><supplementary-material id="d35e617" content-type="local-data"><caption><title><offsets xml_i="58927" xml_f="58944" txt_i="35857" txt_f="35874">Reviewer comments</offsets></title></caption><media mimetype="application" mime-subtype="pdf" xlink:href="bmjopen-2017-017003.reviewer_comments.pdf"></media></supplementary-material><supplementary-material id="d35e618" content-type="local-data"><caption><title><offsets xml_i="59178" xml_f="59197" txt_i="35875" txt_f="35894">Author's manuscript</offsets></title></caption><media mimetype="application" mime-subtype="pdf" xlink:href="bmjopen-2017-017003.draft_revisions.pdf"></media></supplementary-material></sec></body><back><ack id="ack"><p>The authors would like to thank all physicians, nursing staff and clinical research associates of the participating centres for their participation in this study.</p></ack><fn-group><fn fn-type="other"><p><bold>Contributors:</bold> OM conceived the study, coordinated its design and drafted the manuscript. NM and OM wrote the manuscript. DFr, JG, KA, CP, SL, CI, JYL, ML, CDF, JP, DFa, BV, JMC and SS read and were involved in critical appraisal and revision of the manuscript. DFr provided statistical expertise. All authors approved the final manuscript prior to submission.</p></fn><fn fn-type="other"><p><bold>Funding:</bold> This work was supported by a grant from the French Ministry of Social Affairs and Health under number 13-0054. Funder will not have role in the study’s conception or in the data analysis.</p></fn><fn fn-type="COI-statement"><p><bold>Competing interests:</bold> None declared.</p></fn><fn fn-type="other"><p><bold>Ethics approval:</bold> Ethic Committee of University Hospital of Poitiers.</p></fn><fn fn-type="other"><p><bold>Provenance and peer review:</bold> Not commissioned; externally peer reviewed.</p></fn><fn fn-type="other"><p><bold>Data sharing statement:</bold> All data are provided in full in this paper.</p></fn><fn fn-type="other"><p><bold>Collaborators:</bold> Audrey Ambert, Gérard Audibert, Alexandre Bergis, Belaid Bouhemad, Elodie Caumon, Raphael Cinotti, Aminata Diop, Claire-Marie Drevet, Jacques Duranteau, Nathalie Dumont, Arnaud Fourcrier, Thomas Gaillard, Anne-Laure Guérin, Marion Guyon, Stéphane Hecketsweiler, Nadia Imzi, Anna Lamacz, Christian Laplace, Sébastien Leduc, Anthéa Loiez, Sophie Lloret, Pauline Manhes, Jean-Pierre Payen, Sébastien Pilifloury, Antoine Roquilly, Lucie Vettoretti.</p></fn></fn-group><ref-list><title>References</title><ref id="R1"><label>1.</label><mixed-citation publication-type="book">
<person-group person-group-type="author"><name name-style="western"><surname>Charvet-Protat</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Jarliet</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Préaubert</surname><given-names>N</given-names></name></person-group>
<chapter-title>Coût de la qualité et de la non qualité des soins dans les établissements de santé</chapter-title>
<source>Etat Des lieux et propositions</source>, <year>2004</year>.</mixed-citation></ref><ref id="R2"><label>2.</label><mixed-citation publication-type="journal">
<collab>Société française d’anesthésie et de réanimation, Société de réanimation de langue française</collab>. <article-title>The risk for and approaches to control nosocomial infections in ICUs: guidelines from SFAR/SRLF task force on nosocomial infections in ICUs: guidelines from SFAR/SRLF task force on nosocomial infections in ICUs</article-title>. <source>Reanimation</source>
<year>2005</year>;<volume>14</volume>:<fpage>463</fpage>–<lpage>71</lpage>.</mixed-citation></ref><ref id="R3"><label>3.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Osborn</surname><given-names>TM</given-names></name>, <name name-style="western"><surname>Tracy</surname><given-names>JK</given-names></name>, <name name-style="western"><surname>Dunne</surname><given-names>JR</given-names></name>, <etal>et al</etal></person-group>
<article-title>Epidemiology of sepsis in patients with traumatic injury</article-title>. <source>Crit Care Med</source>
<year>2004</year>;<volume>32</volume>:<fpage>2234</fpage>–<lpage>40</lpage>. <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1097/01.CCM.0000145586.23276.0F">doi:10.1097/01.CCM.0000145586.23276.0F</ext-link>
<pub-id pub-id-type="pmid">15640635</pub-id></mixed-citation></ref><ref id="R4"><label>4.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Bronchard</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Albaladejo</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Brezac</surname><given-names>G</given-names></name>, <etal>et al</etal></person-group>
<article-title>Early onset pneumonia: risk factors and consequences in head trauma patients</article-title>. <source>Anesthesiology</source>
<year>2004</year>;<volume>100</volume>:<fpage>234</fpage>–<lpage>9</lpage>.<pub-id pub-id-type="pmid">14739794</pub-id></mixed-citation></ref><ref id="R5"><label>5.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Papia</surname><given-names>G</given-names></name>, <name name-style="western"><surname>McLellan</surname><given-names>BA</given-names></name>, <name name-style="western"><surname>El-Helou</surname><given-names>P</given-names></name>, <etal>et al</etal></person-group>
<article-title>Infection in hospitalized trauma patients: incidence, risk factors, and complications</article-title>. <source>J Trauma</source>
<year>1999</year>;<volume>47</volume>:<fpage>923</fpage>–<lpage>7</lpage>. <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1097/00005373-199911000-00018">doi:10.1097/00005373-199911000-00018</ext-link>
<pub-id pub-id-type="pmid">10568723</pub-id></mixed-citation></ref><ref id="R6"><label>6.</label><mixed-citation publication-type="book">
<person-group person-group-type="author"><name name-style="western"><surname>Dahyot</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Laksiri</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Mimoz</surname><given-names>O</given-names></name></person-group>
<chapter-title>Pneumopathies nosocomiales. Elsevier</chapter-title>
<source>Conférence D’actualisation Du 47ème congrès National D’anesthésie et de Réanimation de la SFAR</source>, <year>2005</year>.</mixed-citation></ref><ref id="R7"><label>7.</label><mixed-citation publication-type="journal">
<collab>American Thoracic Society, Infectious Diseases Society of America</collab>. <article-title>Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia</article-title>. <source>Am J Respir Crit Care Med</source>
<year>2005</year>;<volume>171</volume>:<fpage>388</fpage>–<lpage>416</lpage>. <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1164/rccm.200405-644ST">doi:10.1164/rccm.200405-644ST</ext-link>
<pub-id pub-id-type="pmid">15699079</pub-id></mixed-citation></ref><ref id="R8"><label>8.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Hershman</surname><given-names>MJ</given-names></name>, <name name-style="western"><surname>Cheadle</surname><given-names>WG</given-names></name>, <name name-style="western"><surname>Wellhausen</surname><given-names>SR</given-names></name>, <etal>et al</etal></person-group>
<article-title>Monocyte HLA-DR antigen expression characterizes clinical outcome in the trauma patient</article-title>. <source>Br J Surg</source>
<year>1990</year>;<volume>77</volume>:<fpage>204</fpage>–<lpage>7</lpage>. <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1002/bjs.1800770225">doi:10.1002/bjs.1800770225</ext-link>
<pub-id pub-id-type="pmid">2317682</pub-id></mixed-citation></ref><ref id="R9"><label>9.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Taniguchi</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Koido</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Aiboshi</surname><given-names>J</given-names></name>, <etal>et al</etal></person-group>
<article-title>Change in the ratio of interleukin-6 to interleukin-10 predicts a poor outcome in patients with systemic inflammatory response syndrome</article-title>. <source>Crit Care Med</source>
<year>1999</year>;<volume>27</volume>:<fpage>1262</fpage>–<lpage>4</lpage>. <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1097/00003246-199907000-00005">doi:10.1097/00003246-199907000-00005</ext-link>
<pub-id pub-id-type="pmid">10446817</pub-id></mixed-citation></ref><ref id="R10"><label>10.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Kollef</surname><given-names>MH</given-names></name></person-group>
<article-title>Prevention of hospital-associated pneumonia and ventilator-associated pneumonia</article-title>. <source>Crit Care Med</source>
<year>2004</year>;<volume>32</volume>:<fpage>1396</fpage>–<lpage>405</lpage>. <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1097/01.CCM.0000128569.09113.FB">doi:10.1097/01.CCM.0000128569.09113.FB</ext-link>
<pub-id pub-id-type="pmid">15187525</pub-id></mixed-citation></ref><ref id="R11"><label>11.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Seguin</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Mallédant</surname><given-names>Y</given-names></name></person-group>
<article-title>Prévention des pneumopathies nosocomiales. Congrès national d’anesthésie et de réanimation</article-title>. <source>Les Essentiels</source>
<year>2008</year>:<fpage>495</fpage>–<lpage>506</lpage>.</mixed-citation></ref><ref id="R12"><label>12.</label><mixed-citation publication-type="journal">
<collab>Société française d’anesthésie et de réanimation, Société de réanimation de langue française</collab>. <article-title>5e Conférence de consensus Prévention desDes infections nosocomiales en réanimation — transmission croisée et nouveau-né exclus</article-title>. <source>Réanimation</source>
<year>2010</year>;<volume>19</volume>:<fpage>4</fpage>–<lpage>14</lpage>.</mixed-citation></ref><ref id="R13"><label>13.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Souweine</surname><given-names>B</given-names></name>, <name name-style="western"><surname>Mom</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Traore</surname><given-names>O</given-names></name>, <etal>et al</etal></person-group>
<article-title>Ventilator-associated sinusitis: microbiological results of sinus aspirates in patients on antibiotics</article-title>. <source>Anesthesiology</source>
<year>2000</year>;<volume>93</volume>:<fpage>1255</fpage>–<lpage>60</lpage>.<pub-id pub-id-type="pmid">11046214</pub-id></mixed-citation></ref><ref id="R14"><label>14.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Feldman</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Kassel</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Cantrell</surname><given-names>J</given-names></name>, <etal>et al</etal></person-group>
<article-title>The presence and sequence of endotracheal tube colonization in patients undergoing mechanical ventilation</article-title>. <source>Eur Respir J</source>
<year>1999</year>;<volume>13</volume>:<fpage>546</fpage>–<lpage>51</lpage>. <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1183/09031936.99.13354699">doi:10.1183/09031936.99.13354699</ext-link>
<pub-id pub-id-type="pmid">10232424</pub-id></mixed-citation></ref><ref id="R15"><label>15.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Subirana</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Solà</surname><given-names>I</given-names></name>, <name name-style="western"><surname>Benito</surname><given-names>S</given-names></name></person-group>
<article-title>Closed tracheal suction systems versus open tracheal suction systems for mechanically ventilated adult patients</article-title>. <source>Cochrane Database Syst Rev</source>
<year>2007</year>:<fpage>CD004581</fpage>
<ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1002/14651858.CD004581.pub2">doi:10.1002/14651858.CD004581.pub2</ext-link>
<pub-id pub-id-type="pmid">17943823</pub-id></mixed-citation></ref><ref id="R16"><label>16.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>de Lassence</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Alberti</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Azoulay</surname><given-names>E</given-names></name>, <etal>et al</etal></person-group>
<article-title>Impact of unplanned extubation and reintubation after weaning on nosocomial pneumonia risk in the intensive care unit: a prospective multicenter study</article-title>. <source>Anesthesiology</source>
<year>2002</year>;<volume>97</volume>:<fpage>148</fpage>–<lpage>56</lpage>. <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1097/00000542-200207000-00021">doi:10.1097/00000542-200207000-00021</ext-link>
<pub-id pub-id-type="pmid">12131116</pub-id></mixed-citation></ref><ref id="R17"><label>17.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Girou</surname><given-names>E</given-names></name>, <name name-style="western"><surname>Brun-Buisson</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Taillé</surname><given-names>S</given-names></name>, <etal>et al</etal></person-group>
<article-title>Secular trends in nosocomial infections and mortality associated with noninvasive ventilation in patients with exacerbation of COPD and pulmonary edema</article-title>. <source>JAMA</source>
<year>2003</year>;<volume>290</volume>:<fpage>2985</fpage>–<lpage>91</lpage>. <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1001/jama.290.22.2985">doi:10.1001/jama.290.22.2985</ext-link>
<pub-id pub-id-type="pmid">14665660</pub-id></mixed-citation></ref><ref id="R18"><label>18.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Delaney</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Gray</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Laupland</surname><given-names>KB</given-names></name>, <etal>et al</etal></person-group>
<article-title>Kinetic bed therapy to prevent nosocomial pneumonia in mechanically ventilated patients: a systematic review and meta-analysis</article-title>. <source>Crit Care</source>
<year>2006</year>;<volume>10</volume>:<fpage>R70</fpage>
<ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1186/cc4912">doi:10.1186/cc4912</ext-link>
<pub-id pub-id-type="pmid">16684365</pub-id></mixed-citation></ref><ref id="R19"><label>19.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Goldhill</surname><given-names>DR</given-names></name>, <name name-style="western"><surname>Imhoff</surname><given-names>M</given-names></name>, <name name-style="western"><surname>McLean</surname><given-names>B</given-names></name>, <etal>et al</etal></person-group>
<article-title>Rotational bed therapy to prevent and treat respiratory complications: a review and meta-analysis</article-title>. <source>Am J Crit Care</source>
<year>2007</year>;<volume>16</volume>:<fpage>50</fpage>–<lpage>61</lpage>.<pub-id pub-id-type="pmid">17192526</pub-id></mixed-citation></ref><ref id="R20"><label>20.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Labeau</surname><given-names>SO</given-names></name>, <name name-style="western"><surname>Van de Vyver</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Brusselaers</surname><given-names>N</given-names></name>, <etal>et al</etal></person-group>
<article-title>Prevention of ventilator-associated pneumonia with oral antiseptics: a systematic review and meta-analysis</article-title>. <source>Lancet Infect Dis</source>
<year>2011</year>;<volume>11</volume>:<fpage>845</fpage>–<lpage>54</lpage>. <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/S1473-3099(11)70127-X">doi:10.1016/S1473-3099(11)70127-X</ext-link>
<pub-id pub-id-type="pmid">21798809</pub-id></mixed-citation></ref><ref id="R21"><label>21.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Tantipong</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Morkchareonpong</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Jaiyindee</surname><given-names>S</given-names></name>, <etal>et al</etal></person-group>
<article-title>Randomized controlled trial and meta-analysis of oral decontamination with 2% chlorhexidine solution for the prevention of ventilator-associated pneumonia</article-title>. <source>Infect Control Hosp Epidemiol</source>
<year>2008</year>;<volume>29</volume>:<fpage>131</fpage>–<lpage>6</lpage>. <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1086/526438">doi:10.1086/526438</ext-link>
<pub-id pub-id-type="pmid">18179368</pub-id></mixed-citation></ref><ref id="R22"><label>22.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Heyland</surname><given-names>DK</given-names></name>, <name name-style="western"><surname>Cook</surname><given-names>DJ</given-names></name>, <name name-style="western"><surname>Schoenfeld</surname><given-names>PS</given-names></name>, <etal>et al</etal></person-group>
<article-title>The effect of acidified enteral feeds on gastric colonization in critically ill patients: results of a multicenter randomized trial. canadian critical care Trials Group</article-title>. <source>Crit Care Med</source>
<year>1999</year>;<volume>27</volume>:<fpage>2399</fpage>–<lpage>406</lpage>. <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1097/00003246-199911000-00013">doi:10.1097/00003246-199911000-00013</ext-link>
<pub-id pub-id-type="pmid">10579255</pub-id></mixed-citation></ref><ref id="R23"><label>23.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Valencia</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Ferrer</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Farre</surname><given-names>R</given-names></name>, <etal>et al</etal></person-group>
<article-title>Automatic control of tracheal tube cuff pressure in ventilated patients in semirecumbent position: a randomized trial</article-title>. <source>Crit Care Med</source>
<year>2007</year>;<volume>35</volume>:<fpage>1543</fpage>–<lpage>9</lpage>. <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1097/01.CCM.0000266686.95843.7D">doi:10.1097/01.CCM.0000266686.95843.7D</ext-link>
<pub-id pub-id-type="pmid">17452937</pub-id></mixed-citation></ref><ref id="R24"><label>24.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Duguet</surname><given-names>A</given-names></name>, <name name-style="western"><surname>D’Amico</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Biondi</surname><given-names>G</given-names></name>, <etal>et al</etal></person-group>
<article-title>Control of tracheal cuff pressure: a pilot study using a pneumatic device</article-title>. <source>Intensive Care Med</source>
<year>2007</year>;<volume>33</volume>:<fpage>128</fpage>–<lpage>32</lpage>. <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1007/s00134-006-0417-x">doi:10.1007/s00134-006-0417-x</ext-link>
<pub-id pub-id-type="pmid">17063357</pub-id></mixed-citation></ref><ref id="R25"><label>25.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Nseir</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Duguet</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Copin</surname><given-names>MC</given-names></name>, <etal>et al</etal></person-group>
<article-title>Continuous control of endotracheal cuff pressure and tracheal wall damage: a randomized controlled animal study</article-title>. <source>Crit Care</source>
<year>2007</year>;<volume>11</volume>:<fpage>R109</fpage>
<ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1186/cc6142">doi:10.1186/cc6142</ext-link>
<pub-id pub-id-type="pmid">17915017</pub-id></mixed-citation></ref><ref id="R26"><label>26.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Braz</surname><given-names>JR</given-names></name>, <name name-style="western"><surname>Navarro</surname><given-names>LH</given-names></name>, <name name-style="western"><surname>Takata</surname><given-names>IH</given-names></name>, <etal>et al</etal></person-group>
<article-title>Endotracheal tube cuff pressure: need for precise measurement</article-title>. <source>Sao Paulo Med J</source>
<year>1999</year>;<volume>117</volume>:<fpage>243</fpage>–<lpage>7</lpage>. <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1590/S1516-31801999000600004">doi:10.1590/S1516-31801999000600004</ext-link>
<pub-id pub-id-type="pmid">10625887</pub-id></mixed-citation></ref><ref id="R27"><label>27.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Nseir</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Zerimech</surname><given-names>F</given-names></name>, <name name-style="western"><surname>Fournier</surname><given-names>C</given-names></name>, <etal>et al</etal></person-group>
<article-title>Continuous control of tracheal cuff pressure and microaspiration of gastric contents in critically ill patients</article-title>. <source>Am J Respir Crit Care Med</source>
<year>2011</year>;<volume>184</volume>:<fpage>1041</fpage>–<lpage>7</lpage>. <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1164/rccm.201104-0630OC">doi:10.1164/rccm.201104-0630OC</ext-link>
<pub-id pub-id-type="pmid">21836137</pub-id></mixed-citation></ref><ref id="R28"><label>28.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Abud</surname><given-names>TM</given-names></name>, <name name-style="western"><surname>Braz</surname><given-names>JR</given-names></name>, <name name-style="western"><surname>Martins</surname><given-names>RH</given-names></name>, <etal>et al</etal></person-group>
<article-title>The Lanz endotracheal tube decreases tracheal injury in dogs</article-title>. <source>Can J Anaesth</source>
<year>2005</year>;<volume>52</volume>:<fpage>878</fpage>–<lpage>82</lpage>. <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1007/BF03021785">doi:10.1007/BF03021785</ext-link>
<pub-id pub-id-type="pmid">16189342</pub-id></mixed-citation></ref><ref id="R29"><label>29.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Farré</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Rotger</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Ferre</surname><given-names>M</given-names></name>, <etal>et al</etal></person-group>
<article-title>Automatic regulation of the cuff pressure in endotracheally-intubated patients</article-title>. <source>Eur Respir J</source>
<year>2002</year>;<volume>20</volume>:<fpage>1010</fpage>–<lpage>3</lpage>. <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1183/09031936.02.02692001">doi:10.1183/09031936.02.02692001</ext-link>
<pub-id pub-id-type="pmid">12412697</pub-id></mixed-citation></ref><ref id="R30"><label>30.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Young</surname><given-names>PJ</given-names></name>, <name name-style="western"><surname>Burchett</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Harvey</surname><given-names>I</given-names></name>, <etal>et al</etal></person-group>
<article-title>The prevention of pulmonary aspiration with control of tracheal wall pressure using a silicone cuff</article-title>. <source>Anaesth Intensive Care</source>
<year>2000</year>;<volume>28</volume>:<fpage>660</fpage>–<lpage>5</lpage>.<pub-id pub-id-type="pmid">11153293</pub-id></mixed-citation></ref><ref id="R31"><label>31.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Kay</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Fisher</surname><given-names>JA</given-names></name></person-group>
<article-title>Control of endotracheal tube cuff pressure using a simple device</article-title>. <source>Anesthesiology</source>
<year>1987</year>;<volume>66</volume>:<elocation-id>253</elocation-id>
<ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1097/00000542-198702000-00030">doi:10.1097/00000542-198702000-00030</ext-link>
<pub-id pub-id-type="pmid">3813092</pub-id></mixed-citation></ref><ref id="R32"><label>32.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Nseir</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Lorente</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Ferrer</surname><given-names>M</given-names></name>, <etal>et al</etal></person-group>
<article-title>Continuous control of tracheal cuff pressure for VAP prevention: a collaborative meta-analysis of individual participant data</article-title>. <source>Ann Intensive Care</source>
<year>2015</year>;<volume>5</volume>:<fpage>43</fpage>
<ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1186/s13613-015-0087-3">doi:10.1186/s13613-015-0087-3</ext-link>
<pub-id pub-id-type="pmid">26603289</pub-id></mixed-citation></ref><ref id="R33"><label>33.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Brisson</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Bouhemad</surname><given-names>B</given-names></name>, <name name-style="western"><surname>Monsel</surname><given-names>A</given-names></name>, <etal>et al</etal></person-group>
<article-title>Comparaison De deux systèmes de régulation de la pression Du ballonet de la sonde d’intubation en réanimation: un système mécanique versus un système electrique</article-title>. <source>SRLF</source>
<year>2012</year>.</mixed-citation></ref><ref id="R34"><label>34.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Roquilly</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Cinotti</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Jaber</surname><given-names>S</given-names></name>, <etal>et al</etal></person-group>
<article-title>Implementation of an evidence-based extubation readiness bundle in 499 brain-injured patients. a before-after evaluation of a quality improvement project</article-title>. <source>Am J Respir Crit Care Med</source>
<year>2013</year>;<volume>188</volume>:<fpage>958</fpage>–<lpage>66</lpage>. <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1164/rccm.201301-0116OC">doi:10.1164/rccm.201301-0116OC</ext-link>
<pub-id pub-id-type="pmid">23927561</pub-id></mixed-citation></ref><ref id="R35"><label>35.</label><mixed-citation publication-type="book">
<collab>French Health Authority</collab>. <source>Stratégie D’antibiothérapie et prévention des résistances bactériennes en établissement de santé</source>, <year>2008</year>.</mixed-citation></ref><ref id="R36"><label>36.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Robbins</surname><given-names>RA</given-names></name>, <name name-style="western"><surname>Robbins</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Robbins</surname><given-names>R</given-names></name></person-group>
<article-title>CDC releases ventilator-associated events criteria</article-title>. <source>Southwest Journal of Pulmonary and Critical Care</source>
<year>2017</year>;<volume>14</volume>:<fpage>40</fpage>–<lpage>1</lpage>. <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.13175/swjpcc009-17">doi:10.13175/swjpcc009-17</ext-link>
</mixed-citation></ref><ref id="R37"><label>37.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Seguin</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Laviolle</surname><given-names>B</given-names></name>, <name name-style="western"><surname>Dahyot-Fizelier</surname><given-names>C</given-names></name>, <etal>et al</etal></person-group>
<article-title>Effect of oropharyngeal povidone-iodine preventive oral care on ventilator-associated pneumonia in severely brain-injured or cerebral hemorrhage patients: a multicenter, randomized controlled trial</article-title>. <source>Crit Care Med</source>
<year>2014</year>;<volume>42</volume>:<fpage>1</fpage>–<lpage>8</lpage>. <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1097/CCM.0b013e3182a2770f">doi:10.1097/CCM.0b013e3182a2770f</ext-link>
<pub-id pub-id-type="pmid">24105456</pub-id></mixed-citation></ref><ref id="R38"><label>38.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Asehnoune</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Seguin</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Allary</surname><given-names>J</given-names></name>, <etal>et al</etal></person-group>
<article-title>Hydrocortisone and fludrocortisone for prevention of hospital-acquired pneumonia in patients with severe traumatic brain injury (Corti-TC): a double-blind, multicentre phase 3, randomised placebo-controlled trial</article-title>. <source>Lancet Respir Med</source>
<year>2014</year>;<volume>2</volume>:<fpage>706</fpage>–<lpage>16</lpage>. <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/S2213-2600(14)70144-4">doi:10.1016/S2213-2600(14)70144-4</ext-link>
<pub-id pub-id-type="pmid">25066331</pub-id></mixed-citation></ref><ref id="R39"><label>39.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Moher</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Hopewell</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Schulz</surname><given-names>KF</given-names></name>, <etal>et al</etal></person-group>
<article-title>CONSORT 2010 explanation and elaboration: updated guidelines for reporting parallel group randomised trials</article-title>. <source>BMJ</source>
<year>2010</year>;<volume>340</volume>:<fpage>c869</fpage>
<ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1136/bmj.c869">doi:10.1136/bmj.c869</ext-link>
<pub-id pub-id-type="pmid">20332511</pub-id></mixed-citation></ref><ref id="R40"><label>40.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Kahan</surname><given-names>BC</given-names></name>, <name name-style="western"><surname>Morris</surname><given-names>TP</given-names></name></person-group>
<article-title>Reporting and analysis of trials using stratified randomisation in leading medical journals: review and reanalysis</article-title>. <source>BMJ</source>
<year>2012</year>;<volume>345</volume>:<fpage>e5840</fpage>
<ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1136/bmj.e5840">doi:10.1136/bmj.e5840</ext-link>
<pub-id pub-id-type="pmid">22983531</pub-id></mixed-citation></ref><ref id="R41"><label>41.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Jaillette</surname><given-names>E</given-names></name>, <name name-style="western"><surname>Zerimech</surname><given-names>F</given-names></name>, <name name-style="western"><surname>De Jonckheere</surname><given-names>J</given-names></name>, <etal>et al</etal></person-group>
<article-title>Efficiency of a pneumatic device in controlling cuff pressure of polyurethane-cuffed tracheal tubes: a randomized controlled study</article-title>. <source>BMC Anesthesiol</source>
<year>2013</year>;<volume>13</volume>:<fpage>50</fpage>
<ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1186/1471-2253-13-50">doi:10.1186/1471-2253-13-50</ext-link>
<pub-id pub-id-type="pmid">24369057</pub-id></mixed-citation></ref><ref id="R42"><label>42.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Johanson</surname><given-names>WG</given-names></name>, <name name-style="western"><surname>Pierce</surname><given-names>AK</given-names></name>, <name name-style="western"><surname>Sanford</surname><given-names>JP</given-names></name>, <etal>et al</etal></person-group>
<article-title>Nosocomial respiratory infections with gram-negative bacilli. the significance of colonization of the respiratory tract</article-title>. <source>Ann Intern Med</source>
<year>1972</year>;<volume>77</volume>:<fpage>701</fpage>–<lpage>6</lpage>.<pub-id pub-id-type="pmid">5081492</pub-id></mixed-citation></ref><ref id="R43"><label>43.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Pugin</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Auckenthaler</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Mili</surname><given-names>N</given-names></name>, <etal>et al</etal></person-group>
<article-title>Diagnosis of ventilator-associated pneumonia by bacteriologic analysis of bronchoscopic and nonbronchoscopic ‘blind’ bronchoalveolar lavage fluid</article-title>. <source>Am Rev Respir Dis</source>
<year>1991</year>;<volume>143</volume>:<fpage>1121</fpage>–<lpage>9</lpage>. <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1164/ajrccm/143.5_Pt_1.1121">doi:10.1164/ajrccm/143.5_Pt_1.1121</ext-link>
<pub-id pub-id-type="pmid">2024824</pub-id></mixed-citation></ref><ref id="R44"><label>44.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Miller</surname><given-names>PR</given-names></name>, <name name-style="western"><surname>Johnson</surname><given-names>JC</given-names></name>, <name name-style="western"><surname>Karchmer</surname><given-names>T</given-names></name>, <etal>et al</etal></person-group>
<article-title>National nosocomial infection surveillance system: from benchmark to bedside in trauma patients</article-title>. <source>J Trauma</source>
<year>2006</year>;<volume>60</volume>:<fpage>98</fpage>–<lpage>103</lpage>. <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1097/01.ta.0000196379.74305.e4">doi:10.1097/01.ta.0000196379.74305.e4</ext-link>
<pub-id pub-id-type="pmid">16456442</pub-id></mixed-citation></ref><ref id="R45"><label>45.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Rea-Neto</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Youssef</surname><given-names>NC</given-names></name>, <name name-style="western"><surname>Tuche</surname><given-names>F</given-names></name>, <etal>et al</etal></person-group>
<article-title>Diagnosis of ventilator-associated pneumonia: a systematic review of the literature</article-title>. <source>Crit Care</source>
<year>2008</year>;<volume>12</volume>:<fpage>R56</fpage>–. <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1186/cc6877">doi:10.1186/cc6877</ext-link>
<pub-id pub-id-type="pmid">18426596</pub-id></mixed-citation></ref><ref id="R46"><label>46.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Lorente</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Lecuona</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Jiménez</surname><given-names>A</given-names></name>, <etal>et al</etal></person-group>
<article-title>Continuous endotracheal tube cuff pressure control system protects against ventilator-associated pneumonia</article-title>. <source>Crit Care</source>
<year>2014</year>;<volume>18</volume>:<fpage>R77</fpage>
<ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1186/cc13837">doi:10.1186/cc13837</ext-link>
<pub-id pub-id-type="pmid">24751286</pub-id></mixed-citation></ref><ref id="R47"><label>47.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Nseir</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Zerimech</surname><given-names>F</given-names></name>, <name name-style="western"><surname>Fournier</surname><given-names>C</given-names></name>, <etal>et al</etal></person-group>
<article-title>Continuous control of tracheal cuff pressure and microaspiration of gastric contents in critically ill patients</article-title>. <source>Am J Respir Crit Care Med</source>
<year>2011</year>;<volume>184</volume>:<fpage>1041</fpage>–<lpage>7</lpage>. <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1164/rccm.201104-0630OC">doi:10.1164/rccm.201104-0630OC</ext-link>
<pub-id pub-id-type="pmid">21836137</pub-id></mixed-citation></ref></ref-list></back></article>